CORONAVIRUS

Applicant: THE PIRBRIGHT INSTITUTE, Pirbright, Woking (GB)

Inventors: Erica Bickerton, Woking (GB); Sarah Keep, Woking (GB); Paul Britton, Woking (GB)

Assignee: THE PIRBRIGHT INSTITUTE, Pirbright, Woking (GB)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Appl. No.: 15/328,179

PCT Filed: Jul. 23, 2015

PCT No.: PCT/GB2015/052124

Prior Publication Data
US 2017/0216427 A1 Aug. 3, 2017

Foreign Application Priority Data
Jul. 23, 2014 (GB) 1413020.7

Int. Cl.
A61K 39/215 (2006.01)
C12N 7/00 (2006.01)
C12N 9/12 (2006.01)
A61K 39/00 (2006.01)

U.S. Cl.
CPC A61K 39/215 (2013.01); C12N 7/00 (2013.01); C12N 9/12 (2013.01); C12Y 207/0048 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); C12N 2770/20021 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20051 (2013.01); C12N 2770/20062 (2013.01)

Field of Classification Search
CPC A61K 39/215

References Cited
U.S. PATENT DOCUMENTS
7,452,542 B2 * 11/2008 Denison ............... C07K 14/005 424/221.1

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS
Sperry Journal of Virology, 2005, vol. 79, No. 6, pp. 3391-3400 *
Casas et al., Recombinant avian infectious bronchitis virus expressing a heterologous spike gene demonstrates that the spike protein is a determinant of cell tropism, J. Virol., 77(16):9084-9 (2003).

Primary Examiner — Bao Q Li
Attorney, Agent, or Firm — Marshall, Gerstein & Borun LLP

ABSTRACT
The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.

25 Claims, 15 Drawing Sheets
Specification includes a Sequence Listing.
References Cited

OTHER PUBLICATIONS


* cited by examiner
FIGURE 1

M41 growth curve

Titre (log10 pfu/ml) vs Time (hours)

- M41 R-6
- M41 R-12
- M41 EP4
FIGURE 2

**Snicking**

- mock
- Beau-R
- M41-R 6
- M41-R 12
- M41-CK EP4

Number of snicks per bird per minute

Day 3 | Day 4 | Day 5 | Day 6 | Day 7
--- | --- | --- | --- | ---
0.00 | 0.00 | 1.80 | 1.60 | 1.40

**Wheezeing**

- mock
- Beau-R
- M41-R 6
- M41-R 12
- M41-CK EP4

Percentage of birds affected

Day 3 | Day 4 | Day 5 | Day 6 | Day 7
--- | --- | --- | --- | ---
10 | 10 | 90 | 80 | 70
FIGURE 3

Assessment of Ciliary Activity

Percentage ciliary activity

Day 4  Day 6  Day 7

mock
Beau-R
M41-R 6
M41-R 12
M41-CK EP4
FIGURE 4

Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7

Number of snicks per bird per minute

Mock
M41-R 12
M41R-nsp10rep
M41R-nsp14,15,16rep
M41-CK EP5
FIGURE 5

Mock
M41-R 12
M41R-nsp10rep
M41R-nsp14,15,16rep
M41-CK EP5

Percentage ciliary activity

Day 4
Day 6
FIGURE 7

Percentage of birds affected & M41R - Asp 10, 15 rep 1
M41R - NSP 10, 14, 16 rep 4
M41R - risp 10, 15, 16 rep 8
M41 - 115p 10, 14, 15 rep 10

Day 3 Day 4 Day 5 Day 6 Day 7

Percentage of birds affected

Mock
M41R-nsp 10, 15 rep 1
M41R-nsp 10, 14, 16 rep 4
M41R-nsp 10, 15, 16 rep 8
M41R-nsp 10, 14, 15 rep 10
M41-K 6
M41-CK EP4
FIGURE 8

Percentage ciliary activity

Day 4

Day 6

- mock
- M41R-nsp 10, 15 rep 1
- M41R-nsp 10, 14, 16 rep 4
- M41R-nsp 10, 15, 16 rep 8
- M41R-nsp 10, 14, 15 rep 10
- M41-K 6
- M41-CK EP4
Fig. 10

<p>| | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nsp10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M41 Nsp10: SKGHE TFVDVGILSCLCSFAVDPADTYCKYVAAGNQP IGLMVCRTMLTVHNGSGFAII STKFPSPTPDQDSYGASVCLYCRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mod Nsp10: SKGHE TFVDVGILSCLCSFAVDPADTYCKYVAAGNQP IGLMVCRTMLTVHNGSGFAII STKFPSPTPDQDSYGASVCLYCRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nsp10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M41 Nsp10: HTAGP CGAAGNLGRCQFKGPSVQIPTTKDPVGFCILRNKVCITVCQCWIGYGCQCD SLRQPKPSVC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mod Nsp10: HTAGP CGAAGNLGRCQFKGPSVQIPTTKDPVGFCILRNKVCITVCQCWIGYGCQCD SLRQPKPSVC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
US 10,130,701 B2

CORONAVIRUS

FIELD OF THE INVENTION

The present invention relates to an attenuated coronavirus comprising a variant replicase gene, which causes the virus to have reduced pathogenicity. The present invention also relates to the use of such a coronavirus in a vaccine to prevent and/or treat a disease.

BACKGROUND TO THE INVENTION

Avian infectious bronchitis virus (IBV), the aetiological agent of infectious bronchitis (IB), is a highly infectious and contagious pathogen of domestic fowl that replicates primarily in the respiratory tract but also in epithelial cells of the gut, kidney and oviduct. IBV is a member of the Order Nidovirales, Family Coronavirusae, Subfamily Corona virinae and Genus Gamma coronaviruses; genetically very similar coronaviruses cause disease in turkeys, guinea fowl and pheasants.

Clinical signs of IB include sneezing, tracheal rales, nasal discharge and wheezing. Meat-type birds have reduced weight gain, whilst egg-laying birds lay fewer eggs and produce poor quality eggs. The respiratory infection predisposes chickens to secondary bacterial infections which can be fatal in chicks. The virus can also cause permanent damage to the oviduct, especially in chicks, leading to reduced egg production and quality; and kidney, sometimes leading to kidney disease which can be fatal.

IBV has been reported to be responsible for more economic loss to the poultry industry than any other infectious disease. Although live attenuated vaccines and inactivated vaccines are universally used in the control of IBV, the protection gained by use of vaccination can be lost either due to vaccine breakdown or the introduction of a new IBV serotype that is not related to the vaccine used, posing a risk to the poultry industry.

Further, there is a need in the industry to develop vaccines which are suitable for use in ovo, in order to improve the efficacy and cost-effectiveness of vaccination programmes. A major challenge associated with in ovo vaccination is that the virus must be capable of replicating in the presence of maternally-derived antibodies against the virus, without being pathogenic to the embryo. Current IBV vaccines are derived following multiple passage in embryonated eggs, this results in viruses with reduced pathogenicity for chickens, so that they can be used as live attenuated vaccines. However such viruses almost always show an increased virulence to embryos and therefore cannot be used for in ovo vaccination as they cause reduced hatchability. A 70% reduction in hatchability is seen in some cases.

Attenuation following multiple passage in embryonated eggs also suffers from other disadvantages. It is an empirical method, as attenuation of the viruses is random and will differ every time the virus is passaged, so passage of the same virus through a different series of eggs for attenuation purposes will lead to a different set of mutations leading to attenuation. There are also efficacy problems associated with the process: some mutations will affect the replication of the virus and some of the mutations may make the virus too attenuated. Mutations can also occur in the S gene which may also affect immunogenicity so that the desired immune response is affected and the potential vaccine may not protect against the required serotype. In addition there are problems associated with reversion to virulence and stability of vaccines.

SUMMARY OF ASPECTS OF THE INVENTION

The present inventors have used a reverse genetics approach in order to rationally attenuate IBV. This approach is much more controllable than random attenuation following multiple passages in embryonated eggs because the position of each mutation is known and its effect on the virus, i.e. the reason for attenuation, can be derived.

Using their reverse genetics approach, the present inventors have identified various mutations which cause the virus to have reduced levels of pathogenicity. The levels of pathogenicity may be reduced such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo. Such viruses may be suitable for in ovo vaccination, which is a significant advantage and has improvement over attenuated IBV vaccines produced following multiple passage in embryonated eggs.

Thus in a first aspect, the present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (np)s-10, nsp-14, nsp-15 or nsp-16.

The variant replicase gene may encode a protein comprising one or more amino acid mutations selected from the list of:

- Pro to Leu at position 85 of SEQ ID NO: 6,
- Val to Leu at position 393 of SEQ ID NO: 7,
- Leu to Ile at position 183 of SEQ ID NO: 8,
- Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The replicase gene may encode a protein comprising the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may encode a protein comprising the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6; Val to Leu at position 393 of SEQ ID NO: 7; Leu to Ile at position 183 of SEQ ID NO: 8; and Val to Ile at position 209 of SEQ ID NO: 9.

The replicase gene may comprise one or more nucleotide substitutions selected from the list of:

- C to T at nucleotide position 12137;
- G to C at nucleotide position 18114;
- T to A at nucleotide position 19047; and
- G to A at nucleotide position 20139;

compared to the sequence shown as SEQ ID NO: 1. The coronavirus may be an infectious bronchitis virus (IBV).

The coronavirus may be IBV-41.

The coronavirus may comprise an S protein at least part of which is from an IBV serotype other than M41.

For example, the S1 subunit or the entire S protein may be from an IBV serotype other than M41.

The coronavirus according to the first aspect of the invention has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, such that when the virus is administered to an embryonated egg, it is capable of replicating without being pathogenic to the embryo.
In a second aspect, the present invention provides a variant replicase gene as defined in connection with the first aspect of the invention.

In a third aspect, the present invention provides a protein encoded by a variant coronavirus replicase gene according to the second aspect of the invention.

In a fourth aspect, the present invention provides a plasmid comprising a replicase gene according to the second aspect of the invention.

In a fifth aspect, the present invention provides a method for making the coronavirus according to the first aspect of the invention which comprises the following steps:

(i) transflecting a plasmid according to the fourth aspect of the invention into a host cell;

(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;

(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene; and

(iv) selecting for recombining virus comprising the modified replicase gene.

The recombining virus may be a vaccinia virus.

The method may also include the step:

(v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombining virus from step (iv).

In a sixth aspect, the present invention provides a cell capable of producing a coronavirus according to the first aspect of the invention.

In a seventh aspect, the present invention provides a vaccine comprising a coronavirus according to the first aspect of the invention and a pharmaceutically acceptable carrier.

In an eighth aspect, the present invention provides a method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to the seventh aspect of the invention to the subject.

Further aspects of the invention provide:

use of a coronavirus according to the first aspect of the invention in the manufacture of a vaccine for treating and/or preventing a disease in a subject.

The disease may be infectious bronchitis (IB).

The method of administration of the vaccine may be selected from the group consisting of: eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

Vaccination may be by in ova vaccination.

The present invention also provides a method for producing a vaccine according to the seventh aspect of the invention, which comprises the step of infecting a cell according to the sixth aspect of the invention with a coronavirus according to the first aspect of the invention.

DESCRIPTION OF THE FIGURES

FIG. 1—Growth kinetics of M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) on CK cells

FIG. 2—Clinical signs, snicking and wheezing, associated with M41-R-6 and M41-R-12 compared to M41-CK (M41 EP4) and Beau-R (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

FIG. 3—Ciliary activity of the viruses in tracheal rings isolated from tracheas taken from infected chicks. 100% ciliary activity indicates no effect by the virus; apathogenic, 0% activity indicates complete loss of ciliary activity; complete ciliostasis, indicating the virus is pathogenic (Bars show mock, Beau-R, M41-R 6, M41-R 12, M41-CK EP4 from left to right of each timepoint).

FIG. 4—Clinical signs, snicking, associated with M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK (M41 EP5) (Bars show mock, M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 5—Ciliary activity of M41R-nsp10rep and M41R-nsp14,15,16rep compared to M41-R-12 and M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock; M41-R12; M41R-nsp10rep; M41R-nsp14,15,16rep and M41-CK EP5 from left to right of each timepoint).

FIG. 6—Clinical signs, snicking, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 7—Clinical signs, wheezing, associated with M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14, 15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 8—Ciliary activity of M41R-nsp10, 15rep, M41R-nsp10, 14, 15rep, M41R-nsp10, 14, 16rep, M41R-nsp10, 15, 16rep and M41-K compared to M41-CK in tracheal rings isolated from tracheas taken from infected chicks (Bars show mock, M41R-nsp10,15rep1; M41R-nsp10,14,16rep4; M41R-nsp10,15,16rep8; M41R-nsp10,14,15rep10; M41-K6 and M41-CK EP4 from left to right of each timepoint).

FIG. 9—Growth kinetics of rBVIs compared to M41-CK on CK cells. FIG. 9A shows the results for M41-R and M41-K. FIG. 9B shows the results for M41-nsp10 rep; M41R-nsp14, 15, 16 rep; M41R-nsp10, 15, 16 rep; M41R-nsp10, 14, 15 rep; and M41R-nsp10, 14, 16.

FIG. 10—Position of amino acid mutations in mutated nsp10, nsp15 and nsp16 sequences.

FIG. 11—A) Snicking; B) Respiratory symptoms (wheezing and rales combined) and C) Ciliary activity of rBV M41R-nsp10, 14,16 rep and rBV M41R-nsp10, 14,16 rep compared to M41-CK (Bars show mock, M41R-nsp10,14rep; M41R-nsp10,16rep and M41-K from left to right of each timepoint).

DETAILED DESCRIPTION

The present invention provides a coronavirus comprising a variant replicase gene which, when expressed in the coronavirus, causes the virus to have reduced pathogenicity compared to a corresponding coronavirus which comprises the wild-type replicase gene.

Coronavirus

Gammaporcoronavirus is a genus of animal virus belonging to the family Coronaviridae. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetry.
The genomic size of coronaviruses ranges from approximately 27 to 32 kilobases, which is the longest size for any known RNA virus.

Coronaviruses primarily infect the upper respiratory or gastrointestinal tract of mammals and birds. Five to six different currently known strains of coronaviruses infect humans. The most publicized human coronavirus, SARS-CoV which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections and can also cause gastroenteritis. Middle East respiratory syndrome coronavirus (MERS-CoV) also causes a lower respiratory tract infection in humans. Coronaviruses are believed to cause a significant percentage of all common colds in human adults.

Coronaviruses also cause a range of diseases in livestock animals and domesticated pets, some of which can be serious and are a threat to the farming industry. Economically significant coronaviruses of livestock animals include infectious bronchitis virus (IBV), which mainly causes respiratory disease in chickens and seriously affects the poultry industry worldwide; porcine coronavirus (transmissible gastroenteritis, TGE) and bovine coronavirus, which both result in diarrhoea in young animals. Feline coronavirus has two forms, feline enteric coronavirus is a pathogen of minor clinical significance, but spontaneous mutation of this virus can result in feline infectious peritonitis (FIP), a disease associated with high mortality.

There are also two types of canine coronavirus (CCoV), one that causes mild gastrointestinal disease and one that has been found to cause respiratory disease. Mouse hepatitis virus (MHV) is a coronavirus that causes an epidemic murine illness with high mortality, especially among colonies of laboratory mice.

Coronaviruses are divided into four groups, as shown below:

**Alpha**
- Canine coronavirus (CCoV)
- Feline coronavirus (FeCoV)
- Human coronavirus 229E (HCoV-229E)
- Porcine epidemic diarrhoea virus (PEDV)
- Transmissible gastroenteritis virus (TGEV)
- Human Coronavirus NL63 (NL or New Haven)

**Beta**
- Bovine coronavirus (BCoV)
- Canine respiratory coronavirus (CRCoV)—Common in SE Asia and Micronesia
- Human coronavirus OC43 (HCoV-OC43)
- Mouse hepatitis virus (MHV)
- Porcine haemagglutinating encephalomyelitis virus (HEV)
- Rat coronavirus (Roy). Rat Coronavirus is quite prevalent in Eastern Australia where, as of March/April 2008, it has been found among native and feral rodent colonies.

**Gamma**
- Infectious bronchitis virus (IBV)
- Turkey coronavirus (Bluecomb disease virus)
- Pheasant coronavirus
- Guinea fowl coronavirus

**Delta**
- Bulbul coronavirus (BuCoV)
- Thrush coronavirus (ThCoV)
- Munia coronavirus (MuCoV)
- Porcine coronavirus (PorCoV) HKU15

The variant replicate gene of the coronavirus of the present invention may be derived from an alphacoronavirus such as TGEV; a betacoronavirus such as MHV; or a gammacoronavirus such as IBV.

As used herein the term "derived from" means that the replicate gene comprises substantially the same nucleotide sequence as the wild-type replicate gene of the relevant coronavirus. For example, the variant replicate gene of the present invention may have up to 80%, 85%, 90%, 95%, 98% or 99% identity with the wild type replicate sequence. The variant coronavirus replicate gene encodes a protein comprising a mutation in one or more non-structural protein (nsp)-10, nsp-14, nsp-15 or nsp-16 when compared to the wild-type sequence of the non-structural protein.

**IBV**
Avian infectious bronchitis (IB) is an acute and highly contagious respiratory disease of chickens which causes significant economic losses. The disease is characterized by respiratory signs including gasping, coughing, sneezing, tracheal rales, and nasal discharge. In young chickens, severe respiratory distress may occur. In layers, respiratory distress, nephritis, decrease in egg production, and loss of internal egg quality and egg shell quality are common.

In broilers, coughing and rattling are common clinical signs, rapidly spreading in all the birds of the premises. Morbidity is 100% in non-vaccinated flocks. Mortality varies depending on age, virus strain, and secondary infections but may be up to 60% in non-vaccinated flocks.

The first IBV serotype to be identified was Massachusetts, but in the United States seven serotypes, including Arkansas and Delaware, are currently circulating, in addition to the originally identified Massachusetts type.

The IBV strain Beaudette was derived following at least 150 passages in chick embryos. IBV Beaudette is no longer pathogenic for hatched chickens but rapidly kills embryos.

H120 is a commercial live attenuated IBV Massachusetts serotype vaccine strain, attenuated by approximately 120 passages in embryonated chicken eggs. H152 is another Massachusetts vaccine, and represents an earlier and slightly more pathogenic passage virus (passage 52) during the development of H120. Vaccines based on H120 are commonly used.

**IB QX** is a virulent field isolate of IBV. It is sometimes known as "Chinese QX" as it was originally isolated following outbreaks of disease in the Qingdao region in China in the mid 1990s. Since that time the virus has crept towards Europe. From 2004, severe egg production issues have been identified with a very similar virus in parts of Western Europe, predominantly in the Netherlands, but also reported from Germany, France, Belgium, Denmark and in the UK.

The virus isolated from the Dutch cases was identified by the Dutch Research Institute at Deventer as a new strain that they called D388. The Chinese connection came from further tests which showed that the virus was 99% similar to the Chinese QX viruses. A live attenuated QX-like IBV vaccine strain has now been developed.

IBV is an enveloped virus that replicates in the cell cytoplasm and contains an non-segmented, single-stranded, positive sense RNA genome. IBV has a 27.6 kb RNA genome and like all coronaviruses contains the four structural proteins; spike glycoprotein (S), small membrane pro-
tein (E), integral membrane protein (M) and nucleocapsid protein (N) which interacts with the genomic RNA.

The genome is organised in the following manner: 5'UTR—polymerase (replicase) gene—structural protein genes (S-E-M-N)—UTR 3'; where the UTR are untranslated regions (each ~500 nucleotides in IBV).

The lipid envelope contains three membrane proteins: S, M and E. The IBV S protein is a type II glycoprotein which oligomerizes in the endoplasmic reticulum and is assembled into homotrimer inserted in the virion membrane via the transmembrane domain and is associated through non-covalent interactions with the M protein. Following incorporation into coronavirus particles, the S protein is responsible for binding to the target cell receptor and fusion of the viral and cellular membranes. The S glycoprotein consists of four domains: a signal sequence that is cleaved during synthesis; the ectodomain, which is present on the outside of the virion particle; the transmembrane region responsible for anchoring the S protein into the lipid bilayer of the virion particle; and the cytoplasmic tail.

All coronaviruses also encode a set of accessory protein genes of unknown function that are not required for replication in vitro, but may play a role in pathogenesis. IBV encodes two accessory genes, genes 3 and 5, which both express two accessory proteins 3a, 3b and 5a, 5b, respectively.

The variant replicase gene of the coronavirus of the present invention may be derived from an IBV. For example the IBV may be IBV Beaudette, H120, H52, IB QX, D388 or M41.

The IBV may be IBV M41. M41 is a prototypic Massachusetts serotype that was isolated in the USA in 1941. It is an isolate used in many labs throughout the world as a pathogenic lab strain and can be obtained from ATCC (VR-219). Attenuated variants are also used by several vaccine producers as IBV vaccines against Massachusetts serotypes causing problems in the field. The present inventors chose to use this strain as they had worked for many years on this virus, and because the sequence of the complete virus genome is available; The M41 isolate, M41-Ck, used by the present inventors was adapted to grow in primary chick kidney (CK) cells and was therefore deemed amenable for recovery as an infectious virus from a cDNA of the complete genome. It is representative of a pathogenic IBV and therefore can be analysed for mutations that cause either loss or reduction in pathogenicity.

The genome sequence of IBV M41-Ck is provided as SEQ ID NO: 1.
-continued

GTACATGAAATGCTGCAAAGAAGGGTGACGACCAACACAGCAGAGGTTAGTGTA

TTTTAAAGAAAGCTTCTTTTTCTTAAAAGGCAAATCAATCTTAAGGAT

GATTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT

GTTTATAGTTGATTAATACCAAGGTGGCAGTACTTACCGTAGCTGACACT

AAAAGTCTGCTACTCCTCTCCTGCAAAATATTGAGAGAGTACAAAA

TTTGTCTTTATATACCTTTTACAGAGTTGTTGTTGTTGTTGTTGTTGTTGTT
Replicase

In addition to the structural and accessory genes, two thirds of a coronavirus genome comprises the replicase gene (at the 5' end of the genome), which is expressed as two polyproteins, pp1a and pp1ab, in which pp1ab is an extension product of pp1a as a result of a –1 ribosomal shift mechanism. The two polyproteins are cleaved by two types of virus-encoded proteases usually resulting in 16 non-structural proteins (Nsp1-16); IBV lacks Nsp1 thereby encoding Nsp2-16.

Thus Gene 1 in IBV encodes 15 (16 in other coronaviruses) non-structural proteins (nsp2-16), which are associated with RNA replication and transcription.

The term 'replicase protein' is used herein to refer to the pp1a and pp1ab polyproteins or individual nsp subunits.

The term 'replicase gene' is used herein to refer to a nucleic acid sequence which encodes for replicase proteins.

A summary of the functions of coronavirus nsp proteins is provided in Table 1.

<table>
<thead>
<tr>
<th>Nsp</th>
<th>Protein</th>
<th>Key features</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Conserved within but not between coronavirus genetic groups; potential regulatory functions in the host cell.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Dispersable for MHV and SARS-CoV replication in tissue culture</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Acidic domain; macro domain with ADRP and poly (ADP-ribose)-binding activities; one or two ZBD-containing papain-like proteases; Y domain</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Transmembrane domain</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>3C-like main protease, homodimer</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Transmembrane domain</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Interacts with nsp8 to form a hexadecamer complex</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Noncanonical RNA polymerase; interacts with nsp7 to form a hexadecamer complex</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>ssRNA-binding protein, dimer</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>RNA-binding protein, homododecamer, zinc-binding domain, known to interact with nsp14 and nsp16</td>
<td></td>
</tr>
</tbody>
</table>
The variant replicase gene encoded by the coronavirus of the present invention comprises a mutation in one or more of the sections of sequence encoding nsp-10, nsp-14, nsp-15 or nsp-16.

Nsp-10 has RNA-binding activity and appears to be involved in homoe and heterotypic interactions within other nsps from the pp1a/pp1ab region. It adopts an α/β fold comprised of five α-helices, one 3_10-helix and three β-strands. Two zinc-binding sites have been identified that are formed by conserved cysteine residues and one histidine residue (Cys-74/Cys-77/His-83/Cys-90; Cys-117/Cys-120/Cys-128/Cys-130). The protein has been confirmed to bind single-stranded and double-stranded RNA and DNA without obvious specificity. Nsp-10 can be cross-linked with nsp-9, suggesting the existence of a complex network of protein-protein interactions involving nsp-7, -8, -9 and -10. In addition, nsp-10 is known to interact with nsp-14 and nsp-16.

<table>
<thead>
<tr>
<th>Nsp</th>
<th>Protein</th>
<th>Key features</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>RNA-dependent RNA polymerase</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Zinc-binding domain, NTase, dNTase, 5'-to-3' RNA and DNA helicase, RNA 5' triphosphate</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>3'-to-5' exoribonuclease, zinc-binding domain and N7-methyltransferase</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Uridylic-specific endoribonuclease, homohexamer</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Putative ribose-2-O-methyltransferase</td>
<td></td>
</tr>
</tbody>
</table>

Nsp-14 comprises a 3'-to-5' exoribonuclease (ExoN) active domain in the amino-terminal region. SARS-CoV ExoN has been demonstrated to have metal ion-dependent 3'-to-5' exoribonuclease activity that acts on both single-stranded and double-stranded RNA, but not on DNA. Nsp-14 has been shown to have proof-reading activity. This nsp has also been shown to have N7-methyltransferase (MTase) activity in the carboxyl-terminal region.

Nsp-15 associated NendoU (nudoviral endoribonuclease, specific for U) RNase activity has been reported for a number of coronaviruses, including SARS-CoV, MHV and IIV. The activities were consistently reported to be significantly enhanced by Mg²⁺ ions and there was little activity in the presence of Mg²⁺ and Ca²⁺. NendoU cleaves at the 3' side of uridylic residues in single-stranded and double-stranded RNA. The biologically relevant substrate(s) of coronavirus NendoUs remains to be identified.

Nsp-16 has been predicted to mediate ribose-2'-O-methyltransferase (2'-O-MTase) activity and reverse-genetics experiments have shown that the 2'-O-MTase domain is essential for viral RNA synthesis in HCoV-229E and SARS-CoV. The enzyme may be involved in the production of the cap 1 structures of coronavirus RNAs and it may also cooperate with NendoU and ExoN in other RNA processing pathways. 2'-O-MTase might also methylate specific RNAs to protect them from NendoU-mediated cleavage.

The genomic and protein sequences for nsp-10, -14, -15 and -16 are provided as SEQ ID NO: 2-5 and 6-9, respectively.

(nsp-10 nucleotide sequence - nucleotides 11884-12318 of SEQ ID NO: 1)
(nsp-14 nucleotide sequence - nucleotides 16928-19500 of SEQ ID NO: 1)
Reduced Pathogenicity

The live, attenuated coronavirus of the present invention comprises a variant replicase gene which causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type gene.

The term “attenuated” as used herein, refers to a virus that exhibits said reduced pathogenicity and may be classified as non-virulent. A live, attenuated virus is a weakened replicating virus still capable of stimulating an immune response and producing immunity but not causing the actual illness.

The term “pathogenicity” is used herein according to its normal meaning to refer to the potential of the virus to cause disease in a subject. Typically the pathogenicity of a coronavirus is determined by assaying disease associated symptoms, for example sneezing, snicking and reduction in tracheal ciliary activity.

The term “reduced pathogenicity” is used to describe that the level of pathogenicity of a coronavirus is decreased, lessened or diminished compared to a corresponding, wild-type coronavirus.

In one embodiment, the coronavirus of the present invention has a reduced pathogenicity compared to the parental M41-CK virus from which it was derived or a control coronavirus. The control coronavirus may be a coronavirus with a known pathogenicity, for example a coronavirus expressing the wild-type replicase protein.

The pathogenicity of a coronavirus may be assessed utilising methods well-known in the art. Typically, pathogenicity is assessed by assaying clinical symptoms in a subject challenged with the virus, for example a chicken.

As an illustration, the chicken may be challenged at 8-24 days old by nasal or ocular inoculation. Clinical symptoms, associated with IBV infection, may be assessed 3-10 days post-infection. Clinical symptoms commonly assessed to
determine the pathogenicity of a coronavirus, for example an IBV, by measuring gasping, coughing, sneezing, snicking, depression, ruffled feathers and loss of tracheal ciliary activity.

The variant replicase of the present invention, when expressed in a coronavirus, may cause a reduced level of clinical symptoms compared to a coronavirus expressing a wild-type replicase.

For example a coronavirus expressing the variant replicase may cause a number of snicks per bird per minute which is less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of snicks caused by a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may cause wheezing in less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20% or less than 10% of the number of birds in a flock infected with the a virus expressing the wild type replicase.

A coronavirus expressing a variant replicase according to the present invention may cause clinical symptoms which is at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the level of tracheal ciliary activity in uninfected birds.

A coronavirus expressing a variant replicase according to the present invention may cause clinical symptoms, as defined in Table 2, at a lower level than a coronavirus expressing the wild type replicase.

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBV severity limits based on clinical signs:</td>
</tr>
<tr>
<td>Snicking (sneezing)</td>
</tr>
<tr>
<td>Nasal exudate</td>
</tr>
<tr>
<td>Watery eyes</td>
</tr>
<tr>
<td>Swollen infraorbital sinuses</td>
</tr>
<tr>
<td>Rales (vibration in trachea or branchi region)</td>
</tr>
<tr>
<td>Flushed posture/depressed</td>
</tr>
<tr>
<td>Fluffed up feathers</td>
</tr>
<tr>
<td>Laying and drinking less</td>
</tr>
<tr>
<td>Drinking in excess: evident by fluid filled crop or measured water intake</td>
</tr>
<tr>
<td>Less active but still evade capture</td>
</tr>
<tr>
<td>Weight loss</td>
</tr>
<tr>
<td>Not eating or drinking</td>
</tr>
<tr>
<td>Birds sit alone and does not evade capture</td>
</tr>
<tr>
<td>Severe respiratory distress: e.g., excessive gasping</td>
</tr>
<tr>
<td>Snicking and/or rales for 7d in total</td>
</tr>
</tbody>
</table>

The variant replicase of the present invention, when expressed in a coronavirus, may cause the virus to replicate at non-pathogenic levels in ovo.

While developing vaccines to be administered in ovo to chicken embryos, attention must be paid to two points: the effect of maternal antibodies on the vaccines and the effect of the vaccines on the embryo. Maternal antibodies are known to interfere with active immunization. For example, vaccines with mild strains do not induce protective antibody levels when administered to broiler chickens with maternal antibodies as these strains are neutralized by the maternal antibody pool.

Thus a viral particle must be sufficiently efficient at replicating and propagating to ensure that it is not neutralized by the maternally-derived antibodies against the virus. Maternally-derived antibodies are a finite pool of effective antibodies, which decrease as the chicken ages, and neutralization of the virus in this manner does not equate to the establishment of long-term immunity for the embryo/chick. In order to develop long-term immunity against the virus, the embryo and hatched chicken must develop an appropriate protective immune response which is distinct to the effect of the maternally-derived antibodies.

To be useful for in ovo vaccination, the virus must also not replicate and propagate at a level which causes it to be pathogenic to the embryo.

Reduced pathogenicity in terms of the embryo may mean that the coronavirus causes less reduction in hatchability compared to a corresponding, wild-type control coronavirus. Thus the term “without being pathogenic to the embryo” in the context of the present invention may mean “without causing reduced hatchability” when compared to a control coronavirus.

A suitable variant replicase may be identified using methods which are known in the art. For example comparative challenge experiments following in ovo vaccination of embryos with or without maternally-derived antibodies may be performed (i.e. wherein the layer has or has not been vaccinated against IBV).

If the variant replicase enables the virus to propagate at a level which is too high, the embryo will not hatch or will not be viable following hatching (i.e. the virus is pathogenic to the embryo). A virus which is pathogenic to the embryo may kill the embryo.

If the variant replicase causes a reduction in viral replication and propagation which is too great, the virus will be
neutralised by the maternally-derived antibodies. Subsequent challenge of the chick with IBV will therefore result in the development of clinical symptoms (for example wheezing, snickering, loss of ciliary activity) and the onset of disease in the challenged chick; as it will have failed to develop effective immunity against the virus.

Variant

As used herein, the term ‘variant’ is synonymous with ‘mutant’ and refers to a nucleic acid or amino acid sequence which differs in comparison to the corresponding wild-type sequence.

A variant/mutant sequence may arise naturally, or may be created artificially (for example by site-directed mutagenesis). The variant may have at least 70, 80, 90, 95, 98 or 99% sequence identity with the corresponding portion of the wild type sequence. The variant may have less than 20, 10, 5, 4, 3, 2 or 1% mutation(s) over the corresponding portion of the wild-type sequence.

The term “wild type” is used to mean a gene or protein having a nucleotide or amino acid sequence which is identical with the native gene or protein respectively (i.e. the viral gene or protein).

Identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % identity between two or more sequences. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, Nucleic Acids Research 12:387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid—Chapter 18), FASTA (Atschul et al., 1990, J. Mol. Biol., 403-410) and the GENEWKS suite of comparison tools, ClustalX (see Larkin et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics, 23:2947-2948). Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 ibid, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FESEM Microbiol Lett 1999 174(2): 247-50; FESEM Microbiol Lett 1999 177(1): 187-8 and tatami@ncbi.nlm.nih.gov).

The sequence may have one or more deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent molecule. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the activity is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

| ALIPHATIC | Non-polar       | GAP         | I   | L     | V      |
| Polar- uncharged | CSM | N | Q |

The coronavirus of the present invention may comprise a variant replicase gene which encodes a protein which comprises a mutation compared to any one of SEQ ID NO: 6, 7, 8 or 9 which, when expressed in a coronavirus, causes the virus to have reduced pathogenicity compared to a coronavirus expressing the corresponding wild-type replicase.

The variant replicase gene may encode a protein which comprises at least one or more amino acid mutations in any combination of nsp-10, nsp-14, nsp-15 and nsp-16.

The variant replicase gene of the coronavirus of the present invention may encode a protein comprising a mutation as defined in the M41 mod sequences presented in FIG. 10.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises one or more amino acid mutations selected from the list of: Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8, Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp-2, nsp-3, nsp-6 or nsp-13.

The variant replicase gene of the coronavirus of the present invention may encode a protein which does not comprise a mutation in nsp10 which corresponds to the threonine to isoleucine mutation caused by a mutation at nucleotide position 12,008 in the gene reported by Ammayappan et al. (Arch Virol (2009) 154:495-499).

Ammayappan et al (as above) reports the identification of sequence changes responsible for the attenuation of IBV strain Arkansas DPI. The study identified 17 amino acid changes in a variety of IBV proteins following multiple passages, approx. 100, of the virus in embryonated eggs. It was not investigated whether the attenuated virus (Ark DPI 101) is capable of replicating in the presence of maternally-derived antibodies against the virus in vivo, without being pathogenic to the embryo. Given that this virus was produced by multiple passage in SPF embryonated eggs, similar methodology for classical IBV vaccines, it is likely that this virus is pathogenic for embryos. The virus may also be sensitive to maternally-derived antibodies if the hens were vaccinated with a similar serotype.

The variant replicase gene of the coronavirus of the present invention may encode a protein which comprises any combination of one or more amino acid mutations provided in the list above.

The variant replicase gene may encode a protein which comprises the amino acid mutation Pro to Leu at position 85 of SEQ ID NO: 6.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutation Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutation Val to Ile at position 209 of SEQ ID NO: 9.
The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, and Val to Leu at position 393 of SEQ ID NO: 7.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 Leu to Ile at position 183 of SEQ ID NO: 8.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 85 of SEQ ID NO: 6 and Val to Ile at position 209 of SEQ ID NO: 9.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 10.

The variant replicase gene may encode a protein which comprises the amino acid mutations Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 11.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 12.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6 Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 13.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 14.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 15.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 16.

The variant replicase gene may encode a protein which comprises the amino acid mutations Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 17.

The variant replicase gene may encode a protein which comprises the amino acid mutations Pro to Leu at position 85 of SEQ ID NO: 6, Val to Leu at position 393 of SEQ ID NO: 7 and Val to Ile at position 209 of SEQ ID NO: 18.

The variant replicase gene may encode a protein which comprises the amino acid mutations Val to Leu at position 393 of SEQ ID NO: 7, Leu to Ile at position 183 of SEQ ID NO: 8 and Val to Ile at position 209 of SEQ ID NO: 19.

C to Tat nucleotide position 12137;  
G to Cat nucleotide position 18114;  
T to A at nucleotide position 19047; and  
G to A at nucleotide position 20139;  
compared to the sequence shown as SEQ ID NO: 1.

The nucleotide sequence may comprise the substitution C12137T.  
The nucleotide sequence may comprise substitution G18114C.  
The nucleotide sequence may comprise the substitution T19047A.  
The nucleotide sequence may comprise the substitution G20139A.  
The nucleotide sequence may comprise the substitutions C12137T and G18114C.  
The nucleotide sequence may comprise the substitutions C12137T and T19047A.  
The nucleotide sequence may comprise the substitutions C12137T and G20139A.  
The nucleotide sequence may comprise the substitutions G18114C and T19047A.  
The nucleotide sequence may comprise the substitutions G18114C and G20139A.  
The nucleotide sequence may comprise the substitutions T19047A and G20139A.  
The nucleotide sequence may comprise the substitutions C12137T, G18114C and T19047A.  
The nucleotide sequence may comprise the substitutions C12137T, T19047A and G20139A.  
The nucleotide sequence may comprise the substitutions C12137T, G18114C and G20139A.  
The nucleotide sequence may comprise the substitutions G18114C, T19047A and G20139A.  
The nucleotide sequence may comprise the substitutions C12137T, G18114C, T19047A and G20139A.  
The nucleotide sequence may comprise a substitution which corresponds to the C120081 substitution reported by Ammayappan et al. (as above).  
The nucleotide sequence may be natural, synthetic or recombinant. It may be double or single stranded, it may be DNA or RNA or combinations thereof. It may, for example, be cDNA, PCR product, genomic sequence or mRNA.  
The nucleotide sequence may be codon optimised for production in the host/host cell of choice.  
It may be isolated, or as part of a plasmid, virus or host cell.

Plasmid  
A plasmid is an extra-chromosomal DNA molecule separate from the chromosomal DNA which is capable of replicating independently of the chromosomal DNA. They are usually circular and double-stranded.  
Plasmids, or vectors (as they are sometimes known), may be used to express a protein in a host cell. For example a bacterial host cell may be transfected with a plasmid capable of encoding a particular protein, in order to express that protein. The term also includes yeast artificial chromosomes and bacterial artificial chromosomes which are capable of accommodating longer portions of DNA.  
The plasmid of the present invention comprises a nucleotide sequence capable of encoding a defined region of the replicase protein. It may also comprise one or more additional coronavirus nucleotide sequence(s), or nucleotide sequence(s) capable of encoding one or more other coronavirus proteins such as the S gene and/or gene 3.  
The plasmid may also comprise a resistance marker, such as the guanine xanthine phosphoribosyltransferase gene (gpt) from Escherichia coli, which confers resistance to
mycophenolic acid (MPA) in the presence of xanthine and hypoxanthine and is controlled by the vaccinia virus P7.5 early/late promoter.

Recombinant Vaccinia Virus

The present invention also relates to a recombinant vaccinia virus (rVV) comprising a variant replicase gene as defined herein. The recombinant vaccinia virus (rVV) may be made using a vaccinia-virus based reverse genetics system.

In this respect, the present invention also provides a method for making a viral particle by:

(i) transfecting a plasmid as described in the previous section into a host cell;
(ii) infecting the host cell with a recombining virus comprising the genome of a coronavirus strain with a replicase gene;
(iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombining virus genome to produce a modified replicase gene;
(iv) selecting for recombining viruses comprising the modified replicase gene.

The term ‘modified replicase gene’ refers to a replicase gene which comprises a variant replicase gene as described in connection with the first aspect of the present invention. Specifically, the term refers to a gene which is derived from a wild-type replicase gene but comprises a nucleotide sequence which causes it to encode a variant replicase protein as defined herein.

The recombination may involve all or part of the replicase gene. For example the recombination may involve a nucleotide sequence encoding for any combination of nsp-10, nsp-14, nsp-15 and/or nsp-16. The recombination may involve a nucleotide sequence which encodes for an amino acid mutation or comprises a nucleotide substitution as defined above.

The genome of the coronavirus strain may lack the part of the replicase protein corresponding to the part provided by the plasmid, so that a modified protein is formed through insertion of the nucleotide sequence provided by the plasmid.

The recombining virus is one suitable to allow homologous recombination between its genome and the plasmid. The vaccinia virus is particularly suitable as homologous recombination is routinely used to insert and delete sequences for the vaccinia virus genome.

The above method optionally includes the step:

(v) recovery of recombinant coronavirus comprising the modified replicase gene from the DNA from the recombinant virus from step (iv).

Methods for recovering recombinant coronavirus, such as recombinant IBV, are known in the art (See Britton et al (2005) see page 24; and PCT/GB2010/001293).

For example, the DNA from the recombining virus from step (iv) may be inserted into a plasmid and used to transfect cells which express cytoplasmic T7 RNA polymerase. The cells may, for example be pre-infected with a fowlpox virus expressing T7 RNA polymerase. Recombinant coronavirus may then be isolated, for example, from the growth medium.

When the plasmid is inserted into the vaccinia virus genome, an unstable intermediate is formed. Recombinants comprising the plasmid may be selected for e.g. using a resistance marker on the plasmid. Positive recombinants may then be verified to contain the modified replicase gene by, for example, PCR and sequencing.

Large stocks of the recombining virus including the modified replicase gene (e.g. recombinant vaccinia virus, (rVV) may be grown up and the DNA extracted in order to carry out step (v)).


Cell

The coronavirus may be used to infect a cell. Coronavirus particles may be harvested, for example from the supernatant, by methods known in the art, and optionally purified.

The cell may be used to produce the coronavirus particle. Thus the present invention also provides a method for producing a coronavirus which comprises the following steps:

(i) infection of a cell with a coronavirus according to the invention;
(ii) allowing the virus to replicate in the cell; and
(iii) harvesting the progeny virus.

The present invention also provides a cell capable of producing a coronavirus according to the invention using a reverse genetics system. For example, the cell may comprise a recombining virus genome comprising a nucleotide sequence capable of encoding the replicase gene of the present invention.

The cell may be employed to produce recombinant recombinating virus (e.g. vaccinia virus) containing the replicase gene. Alternatively the cell may be employed to produce recombinant coronavirus by a reverse genetics system. The cell may be used to express or be induced to express T7 polymerase in order to rescue the recombinant viral particle.

Vaccine

The recombinant may be used to produce a vaccine. The vaccine may by a live attenuated form of the coronavirus of the present invention and may further comprise a pharmaceutically acceptable carrier. As defined herein, “pharmaceutically acceptable carriers” suitable for use in the invention are well known to those of skill in the art. Such carriers include, without limitation, water, saline, buffered saline, phosphate buffer, alcohol/aqueous solutions, emulsions or suspensions. Other conventionally employed diluents and excipients may be added in accordance with conventional techniques. Such carriers can include ethanol, polyols, and suitable mixtures thereof, vegetable oils, and injectable organic esters. Buffers and pH adjusting agents may also be employed. Buffers include, without limitation, salts prepared from an organic acid or base. Representative buffers include, without limitation, organic acid salts, such as salts of citric acid, e.g., citrates, ascorbic acid, glucic acid, histidine-HCl, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Iris, trimethamine hydrochloride, or phosphate buffers. Parenteral carriers can include sodium chloride solution, Ringer’s dextrose, dextrose, trehalose, sucrose, and sodium chloride, lactated Ringer’s or fixed oils. Intravenous carriers can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer’s dextrose and the like. Preservatives and other additives such as, for example, antimicrobials, antioxidants, chelating agents (e.g., EDTA), inert gases and the like may also be provided in the pharmaceutical carriers. The present invention is not limited by the selection of the carrier. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional char-
characteristics is within the skill of the art. See, e.g., texts such as Remington: The Science and Practice of Pharmacy, 20th ed, Lippincott Williams & Wilkins, publ., 2000; and The Handbook of Pharmaceutical Excipients, 4.sup.th edit., eds. R. C. Rowe et al, APhA Publications, 2003.

The vaccine of the invention will be administered in a “therapeutically effective amount”, which refers to an amount of an active ingredient, e.g., an agent according to the invention, sufficient to effect beneficial or desired results when administered to a subject or patient. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition according to the invention may be readily determined by one of ordinary skill in the art. In the context of this invention, a “therapeutically effective amount” is one that produces an objectively measured change in one or more parameters associated with bronchitis condition sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations.

For purposes of this invention, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to reduce the incidence of Infectious Bronchitis. As used herein, the term “therapeutic” encompasses the full spectrum of treatments for a disease, condition or disorder. A “therapeutic” agent of the invention may act in a manner that is prophylactic or preventive, including those that incorporate procedures designed to target animals that can be identified as being at risk (pharmacogenetics); or in a manner that is ameliorative or curative in nature; or may act to slow the rate or extent of the progression of at least one symptom of a disease or disorder being treated.

The present invention also relates to a method for producing such a vaccine which comprises the step of infecting cells, for example Vero cells, with a viral particle comprising a replicase protein as defined in connection with the first aspect of the invention.

Vaccination Method
The coronavirus of the present invention may be used to treat and/or prevent a disease. To “treat” means to administer the vaccine to a subject having an existing disease in order to lessen, reduce or improve at least one symptom associated with the disease and/or to slow down, reduce or block the progression of the disease. To “prevent” means to administer the vaccine to a subject who has not yet contracted the disease and/or who is not showing any symptoms of the disease to prevent or impair the course of the disease (e.g. infection) or to reduce or prevent development of at least one symptom associated with the disease.

The disease may be any disease caused by a coronavirus, such as a respiratory disease and/or gastrointestinal diseases in humans and hepatitis, gastroenteritis, encephalitis, or a respiratory disease in other animals.

The disease may be infectious bronchitis (IB); Porcine epidemic diarrhoea; Transmissible gastroenteritis; Mouse hepatitis virus; Porcine haemagglutinating encephalomyelitis; Severe acute respiratory syndrome (SARS); or Blue-coat disease.

The disease may be infectious bronchitis.

The vaccine may be administered to hatched chicks or chickens, for example by eye drop or intranasal administration. Although accurate, these methods can be expensive e.g. for large broiler flocks. Alternatives include spray inoculation of administration to drinking water but it can be difficult to ensure uniform vaccine application using such methods.

The vaccine may be provided in a form suitable for its administration, such as an eye dropper for intraocular use. The vaccine may be administered by in ovo inoculation, for example by injection of embryonated eggs. In ovo vaccination has the advantage that it provides an early stage resistance to the disease. It also facilitates the administration of a uniform dose per subject, unlike spray inoculation and administration via drinking water.

The vaccine may be administered to any suitable compartment of the egg, including allantoic fluid, yolk sac, amnion, air cell or embryo. It may be administered below the shell (aircell) membrane and chorioallantoic membrane. Usually the vaccine is injected into embryonated eggs during late stages of embryonic development, generally during the first quarter of the incubation period, such as 3-4 days prior to hatch. In chickens, the vaccine may be administered between day 15-19 of the 21-day incubation period, for example at day 17 or 18.

The process can be automated using a robotic injection process, such as those described in WO 2004/078203.

The vaccine may be administered together with one or more other vaccines, for example, vaccines for other diseases, such as Newcastle disease virus (NDV). The present invention also provides a vaccine composition comprising a vaccine according to the invention together with one or more other vaccine(s). The present invention also provides a kit comprising a vaccine according to the invention together with one or more other vaccine(s) for separate, sequential or simultaneous administration.

The vaccine or vaccine composition of the invention may be used to treat a human, animal or avian subject. For example, the subject may be a chick, chicken or mouse (such as a laboratory mouse, e.g. transgenic mouse).

Typically, a physician or veterinarian will determine the actual dosage which will be most suitable for an individual subject or group of subjects and it will vary with the age, weight and response of the particular subject(s).

The composition may optionally comprise a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise (or in addition to) the carrier, excipient or diluent, any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase the delivery or immunogenicity of the virus.

The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

EXAMPLES

Example 1—Generation of an IBV Reverse Genetics System Based on M41-CK

A M41-CK full-length cDNA was produced by replacement of the Beaudette cDNA in the Vaccinia virus reverse genetics system previously described in PCT/GB2010/001293 (herein incorporated by reference) with synthetic cDNA derived from the M41 consensus sequence.

The IBV cDNA within recombinant Vaccinia virus (rVV) rVV-BeauR-Rep-M41 structure described in Armetto, Cavanagh and Britton (2000). PLoS ONE 4(10): e7384. doi:10.1371/journal.pone.0007384, which consisted of the replicase derived from IBV Beaudette strain and the struc-
Example 2—Determining the Pathogenicity of Rescued M41 Viruses

The viruses rescued in Example 1 were used to infect 8-day-old specific pathogen free (SPF) chicks by ocular and nasal inoculation to test them for pathogenicity, as observed by clinical signs on a daily basis 3-7 days post-infection and for ciliary activity days 4 and 6 post-infection. Loss of ciliary activity is a well-established method for determining the pathogenicity of IBV. The two M41-R viruses were found to be apathogenic when compared to M41-CCK though they did show some clinical signs in comparison to uninfected control chicks (Fig. 2) and some inconsistent loss in ciliary activity (Fig. 3).

Thus, the M41-R molecular clones of M41-CCK were not pathogenic when compared to the parental virus M41-CCK.

The inventors identified several nucleotide differences in the M41-R compared to the M41-CCK sequences. The majority of these were synonymous mutations, as the nucleotide change did not affect the amino acid sequence of the protein associated with the sequence. However, four non-synonymous mutations were identified in the IBV replicate gene specific to Nsp10, Nsp14, Nsp15 and Nsp16 components of the replicate gene, these mutations resulted in amino acid changes (Table 3).

TABLE 3-continued

<table>
<thead>
<tr>
<th>Region of Replicase</th>
<th>Nucleotide position</th>
<th>Nucleotide Mutation</th>
<th>Amino Acid Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nsp10</td>
<td>12137</td>
<td>C→T</td>
<td>Phe→Leu</td>
</tr>
<tr>
<td>Nsp14</td>
<td>18114</td>
<td>G→C</td>
<td>Val→Leu</td>
</tr>
</tbody>
</table>

In order to determine whether the identified mutations were responsible for the loss of pathogenicity associated with M41-R, the Nsp10 mutation was repaired and the mutations in Nsp14, -15 & -16 were repaired and shown to grow in a similar manner as M41-CCK (FIG. 9). The inventors thus generated the rIBVs, M41R-nsp10rep and M41R-nsp14, 15, 16rep, using synthetic cDNAs containing the correct nucleotides utilising the inventor's previous described (TDS) system (see PCT/GB2010/001293). The rIBVs were assessed for pathogenicity in chicks as described previously. Both rIBVs showed increased pathogenicity when compared to M41-R but not to the level observed with M41-CCK (FIGS. 4 and 5). M41R-nsp14, 15, 16rep gave more clinical signs and more reduction in ciliary activity than M41R-nsp10rep, overall these results indicated that the changes associated with the four NspS appear to affect pathogenicity.

To determine the roles of the NspS in pathogenicity the full-length cDNA corresponding to M41R-nsp10rep was used to repair the mutations in Nsp14, 15 & 16 using a synthetic cDNA containing the correct nucleotides utilising the TDS system.

The following rIBVs were produced:
M41R-nsp10, 15rep—M41-R with the mutations in Nsp10 and Nsp-15 repaired
M41R-nsp10, 14, 15rep—M41-R with mutations in Nsp10, -14 and -15 repaired
M41R-nsp10, 14, 16rep—M41-R with mutations in Nsp10, -14 and -16 repaired
M41R-nsp10, 15, 16rep—M41-R with mutations in Nsp10, -15 and -16 repaired
M41-K—All four mutations, Nsp10, -14, -15 & -16 repaired in M41-R

The rIBVs were shown to grow in a similar manner as M41-CCK (FIG. 9) and assessed for pathogenicity as described previously. M41-K (in which all four mutations had been repaired) resulted in clinical signs and 100% loss of ciliary activity (complete ciliostasis) by 4 days post-infection (FIGS. 6, 7 & 8). The other rIBVs demonstrated varying levels of pathogenicity, apart from M41R-nsp10, 15, 16rep, which was essentially apathogenic. These results confirmed that repair of all four NspS restored pathogenicity to M41-R; again supporting the previous evidence that the mutations described in the four NspS are implicated in attenuating M41-CCK.

The inventors also generated rIBV M41R-nsp 10, 14 rep (nsp 10 and 14 are repaired, nsp 15 and 16 contain mutations) and rIBV M41R-nsp 10, 16 rep (nsp 10 and 16 are repaired, nsp 14 and 15 contain mutations) and assessed the pathogenicity of these viruses.

rIBV M41R-nsp 10, 14 rep less pathogenic than M41-K but caused around 50% ciliostasis on days 4-6 post-infection. rIBV M41R-nsp 10, 16 rep was almost apathogenic and caused no ciliostasis (see FIG 11A-c).
Thus the genome associated with M41-R is a potential backbone genome for a rationally attenuated IBV.

Example 4—Vaccination/Challenge Study with M41-R

Candidate vaccine viruses were tested in studies in which fertilized chicken eggs were vaccinated in ovo at 18 days embryonation and in which the hatchability of the inoculated eggs was determined. The clinical health of the chickens was investigated and the chickens were challenged at 21 days of age with a virulent IB M41 challenge virus at $10^{3.65} \text{EID}_{50}$ per dose.

Clinical signs were investigated after challenge protection by the vaccine and a ciliostasis test was performed at 5 days after challenge to investigate the effect of the challenge viruses on movement of the cilia and protection by the vaccine against ciliostasis (inhibition of cilia movement).

In Ovo Vaccination in Commercial Broiler Eggs

The design of the experiment is given in Table 4 and the clinical results are given in Table 5. Hatchability of the eggs inoculated with IB M41-R was good and chickens were healthy. IB M41-R protected against clinical signs after challenge in the broilers (placebo: 19/19 affected, IB M41-R: 3/18 affected and 1 dead). The results of the ciliostasis test are given in Table 6. IB M41-R generated protection against ciliostasis.

### Table 4

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
<th>EID$_{50}$</th>
<th>Route</th>
<th>Day(s)</th>
<th>Day(s)</th>
<th>End</th>
<th>Nr. of Eggs per treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>T01</td>
<td>None</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>30</td>
</tr>
<tr>
<td>T02</td>
<td>IB M41-R</td>
<td>$10^7$</td>
<td>In ovo</td>
<td>18 days</td>
<td>At 21 days</td>
<td>At 26</td>
<td>30</td>
</tr>
<tr>
<td>NTX</td>
<td>Saline</td>
<td>NA</td>
<td>In ovo</td>
<td>embryo-</td>
<td>children of age, 20</td>
<td>days</td>
<td>30</td>
</tr>
</tbody>
</table>

*Dose volume 0.1 ml, NA, not applicable.

### Table 5

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Hatch/total</th>
<th>Viral/total</th>
<th>Deaths/total</th>
<th>Symptoms/total</th>
<th>Deaths/total</th>
<th>Symptoms/total</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>28/30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB M41-R</td>
<td>28/30</td>
<td>28/28</td>
<td>1/20</td>
<td>0/19</td>
<td>0/19</td>
<td>3/18</td>
</tr>
<tr>
<td>Saline</td>
<td>20/30</td>
<td>20/29</td>
<td>1/20</td>
<td>0/19</td>
<td>0/19</td>
<td>19/19</td>
</tr>
</tbody>
</table>

*Disturbed respiratory system
*Whirring
*Change of voice
*Breathing difficult
*Swollen intra-orbital sinuses
*Uneven growth
*Weak

In Ovo Vaccination in Specific Pathogen-Free (SPF) Eggs

The design of the study in SPF eggs is given in Table 7 and is similar with the design of the studies with commercial broilers, but the vaccination dose for IB M41-R was higher, $(10^7 \text{EID}_{50}$ per dose).

The results (Table 8) show that the hatch percentage for IB M41-R hatch was low, and 19 of 40 hatched and the chicks were weak. Eight chicks died. The remaining 11 chickens were challenged and 11 of the chicks hatched from the eggs which had been inoculated with saline were challenged.

In the ciliostasis test after challenge it appeared that all chickens vaccinated in ovo with IB M41-R were protected, whereas none of the controls was protected, see Table 9.
In conclusion, IB M41-R was safe in commercial eggs, generated protection against clinical signs and to an extent against ciliostasis.

In SPF eggs vaccinated with IB M41 R a relatively low number of chickens hatched. This may be due to the $10^5$ EID$_{50}$ per egg of IB M41-R used. This was 10-fold higher than the dose used in earlier studies in which there was a higher level of hatchability. The lower hatch percentages may also be caused by a particularly high susceptibility of the hatch of SPF eggs for viruses, as in other studies the level of embryo mortality was also higher that had previously been observed.

After challenge all surviving chickens after hatch were completely protected against ciliostasis. It is concluded that IB M41-R has great potential as vaccine to be administered in ovo.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology, virology or related fields are intended to be within the scope of the following claims.
...
aaagccagtt ttgacgatct tacgtacttt gaaacagtgtt atgataagca cactctcttg 5100
agctctaaag tgcagaggac acctgataat cttgtataat atggtctatt taccgaaag 5160
gaagattcga agttggcaact gacatcctaa gttagaggtta tcaatacagt tggtagacttt 5220
aggtcataag agttggttac tataagttta acacotgata ctgatgaaaaa tccaaacaac 5280
ccagtctact accctgattt ggatcctatt agctctaggg caatatggtt tgaagcagttt 5340
gctaatgttc tggctggtgca tccaaatatt tatagtaagtt cttcgcgaat tccccgctttt 5400
tggaataagt ccgagaggtt tggtaaataag gtgtatatag ttgaggtgttt aactatgggc 5460
cattgtgggt cagaacaccc ttaataaacc aatattgaga gaatattttta catgctcaag 5520
aaagtcatggt tgggacataag tggtaaatct aacgcaatgtg ttaaataact agttaaagca 5580
gcacatagcc tggctgatca acggctcaat tgtgaaaaag aaatgtcctt aacaatctca 5640
aaacacctgt tcacctcttt ctttatttac ttaaagctta gttgaagagtt tttgtttcctt 5700
agctataaga tgtggttatg taaagctggtt ttgctatcct tctattatgt gtgtatttata 5760
tacaacagta atccagactg gtttactggtg atagctgtgc tagactcctt attggaagtt 5820
tctttatgttc gccttctaaag tcagcaagctt gaaagctcttt tttgagttgtt 5880
goaggtattt tcaatcgtctc tgtgtttttta cattgatagac attcacactc tctgctacaa 5940
cattgcttata gcgtgaaaca aattataag gatgcaagcttt cttggattttt aatttttgaag 6000
attgctttt attttgttcct tcaataatata tttgtaagc cattggcagat tttttgatttt 6060
atttgtatt gtgttaagtt tttgtttgatg agttcactct gttgcaacac tgggttttga 6120
tttctagatt gttggttttta aacattttttta accatttttt aattattgag acgggacttt 6180
tatctcggc tcttcttacaa gatataagtt caagtctcatc atattttgta ctgtaagqag 6240
tgtaacattg aggtgtcagc gcagctgtca cgaagacactt taggtgttga 6300
gttggtgtag ccgaagcata agttcagttt tacaataatt ctggcatataaa tttttaaag 6360
agactaatg gatttattgat aataaagtctt atggatgttag accaataaca atattaacttc 6420
cuttaagggc ttggagagct ttggaagaaa cttaaagggc cttttttttta tccaacattat 6480
gttacacag tggctgatac gcggcatgtt gttgattttt tttgtaaaat tttttattttta 6540
gtcgaactcc tggtagctca tctgctatct tttggaatg ttttggctag tttacagtaa 6600
littattataa aacgtttgctt cttgaagagc ctggatagttc aatcaacta 6660
gtttattgag tggtaaatac acagagcgct gcgtcataag aggaagaaaaa gacattggcc 6720
gcttttagt cgcgaatatt ctggaagacctg ataatttatt gacatcatac 6780
catttaagct agactgtcatt gttgtaacct gcagactctct accctgttag 6840
catttaactg tgaagcagatt ctcgtaaaatg tttatgattt tttttttttttttttttttttt 6900
aattataaat cttgtagatac tgcagacttaa attaataag cgggacactt tcagttggtac 6960
cgtttttaca ttaactaagaa cgcagacagc ctagatattg ctatctctctg coaccactat 7020
gaaggtgtac acactgtgga cgcgttttacct aaggctaatggc cgtcataagc ttagcagact 7080
gataagtgta cacccctgtg tagagggttt ttgtaaataag cagatcctc tttttctatt 7140
ttaaagcgtc aaaaagctcc tccggtagga tggaaagttttt ctagctattaa taatttgctt 7200
gcagctgtcc ttaaaatattt aatattgcat atcggacagt cggagctgg ttttttatata 7260
amaagttctg ttgctaatca aggattcttct tgcctactcc agaaactatt ggtagagaga 7320
aaacccgtgg tggctaatatt cttaactttttta aatagttttta tggatttttta ttaattttttttttt 7380
ttggcttttt attataatttt tcaagctagtt tgttgggttt actactataa ggaagatgaaat 7440
aaagaagttgg ttccacccat gtatgagta aactccacac tgcagttgga agggttcaca 7500
gttatacaca aaggttggtt tagagaggtt gttgcgaag ataatgtgttt cttcaattg 7560
tttgataatt tggagcctt ttgggttaaa tcatatgaag atatatataaa atgctcaattt 7620
gttacagggt ttagatagtt cagagccgaca gtagctgttg gttgctcccc ttttgatca 7680
ttgagttttg atggttttggt gttgtgctat gtagacaca gtagctgtag aatcctgttc 7740
attcctacct ggttttaact aaagaaagtt gttgctaccc agagttcaat tataacagtg 7800
ggtatgtttt atacattcct atgtatatttt tctggtatag ttttatatttt aacagccagc 7860
aatccacccct attgctatgtg ttttatgtgc gacaaagtgtc cagcctggacc cttaccattt 7920
gtgtatattct ttcctcataag atgataatcc caacataatag tggttagacct tataatctca 7980
caacaaatatt gtcataacccctctcatactg gtgtggcttgg caaggtgttca 8040
aggtatgtgg atgatctacaaccaggttttac ggattcgtac tagtactcaca atggggttgg 8100
ttattaagtag aatacattgtg taaaacctggcgtttctgttg gttcaacatg tataaatctt 8160
atgattttata gttgttacagc ggatgtttttattttttttaaataaaaggt ccaatgtttt 8220
goactacttg ttttatattg atggtgttttttg gttgtaattt tgcgctgcgtcaattgaatttg 8280
caggtgtttt ttttttattttgcttttcattgatttgtaatttattattataa 8340
aatgtcattgt ttggtgtgttt aatagttattt actatgttatt tataattttta 8400
cctcattgttc aagacacgcttgagttctggtg tgcctgtaattt 8460
cctccttttta ctctgtctttttaaaatatactgccat ccaactgttttgcctgatttt 8520
atcccttattg tgcctgccttc atgggtttttg gttgctttttc tattgtacttttaaatactgg 8580
aagttgatttac ggcaacaggcttttgttg attttttatgcttggtttctgtaattt 8640
gttattgtg tggatgttgtacttgcagttc attggtgatatggcatttttttttta 8700
tatctctctc ctaatgtgtatt accctatattctctggggtcccctgagaactac 8760
tgtaagcatt gcctggctgtt ggcaccatatttttgcttccctgctgggtgattttaa 8820
gaggtgtttttt atttccacccctctcagcaaggtgttattgtggtttatgctttttctg 8880
aaaataagtttt cttcttctttag tgggtgttatgcagttctgctttcactgaaccaccagggtggtgat 8940
gggcataatct ttaatgtgact ttgagctgttttttgttttttttatgctttttctctcttattttatggattttattttttccttctgggtttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
gttaggttac agtccttttct ttgaagaaaa gctacatcct ggtttgtggg tagatgtgta
gttacgtgt ctcttctttccttgtaagaaa gctacatcct ggtttgtggg
tttatagct atcgacgtct aaccaagctt gctacatcct gcgacacatc
gttatgaagttt ctctattctctgctagacttaggtctttcagagat
agtactttcatctagtaggctttcctttacatcactacactacactacactaacatgtctttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
tgtaccagca ggtttattagg cgagtcaatt ttgaccocag atttgtctaa aagcttttat 14580
ctatttctgg taagaaacct tcattgatga ttctgtcga cgaagcgcgtt gttttgtata 14640
acaacacatt agccaaacac ggttgtttag cagatttttc ggttttttaa gaagttctct 14700
actatcggaa caatttttttc atgggtctatt ctaatgtgtg ggttgaaccg gatttgaaga 14760
agacccacaa tgaatatttct tcacagcaaa caatggtttt ggaggtttag ggtgagccat 14820
gattcctgcc atacacgcac cccacacgtta tttttgtgct atgttttttt gtagtgatt 14880
tggtaagac gaaatcctgtg gctgttatgg agctgttatg cgctttgccc atagatgcgt 14940
acccacactgt acatcatgaa aatggagagt acaaagaggt atctcttggt tgttttctcat 15000
acataagaaa acctcatcaca gageggcctc agaatagctgt tattgaactt ttttttgtaa 15060
tggtatatga taaggctagt aatatttggg cacagaggtt ctaaggaac atgatagag 15120
coccaacagc actacagctt tgtgctgttt ttgtctgttg taataagctaa actacttgcg 15180
gctgttgctg tgtcatagcc ccaccatcttt tgcttgctaa gttggctgtat gccacgtcga 15240
tgcaacagaa ccacaaaaat gttttgctca taatacttta cattaggctca cagccaggtt 15300
gttggaagne agatgtactc aatagtaccc tggaggtgtatt gcataacctc tgggtgaacc 15360
atatccacaa gttatccata cccgttagct atcaagttgac atgttttgag aaattcagggg 15420
tcaatgtgc agtttaggaa aatgagtgat atatattcctg acctactctt ttaattttggg 15480
taatctgttte acctatttatt ttggcaaatc gtttgtagaa ttcggtttaga cgttttgtgc 15540
cagagagcaag aagtggaata caagagtactt aaaaaagacgt cgaagcaag 15600
gagaatgtct ttgaagtctt gatgttcttg tgccttttgga gcctagttaa acaagggctc 15660
cattggaataa aatattgtgt ttcaacgtct ctaacccctacta gataagtgtt aaagttgca 15720
tcgggtattc tccacattgg aaaaagtcag tgaagagctt tgtctattat cagagcagtt 15780
tactcgacta attgttgtgt ggagacattt tccttaattac ccaccacatg gttttttcct 15840
tatagcggcc aaggttgtgt gcctacgaca ccccttcttg tgtttgtgaa ttaacagctct 15900
atgtgtagt acgtcggtgt tttgaantaac atcctccatt tcacacttta gtagcggac 15960
agaagcctac tacaagcaca gcggccctgg gcaggtgttaa atcctcaatttt gctaataggt 16020
tggccgctta ctttaagac cggcggcttg ttctttacct gcagctgttg 16080
atgttttag rggaaaaagct tttaagttgc tttgactttta gtaattgact tggatagctt 16140
tcaacaagcct tacatccgg tgcctttctta agttagcaac taattgacaca cgcacaaagtt 16200
acatattttt ttaactaatgact gctttgcaag aagttgcttg tggctaatctt tgggtgcaag 16260
aggttagttat ggtgaaactat caagattgct cttttattaa tagttgaagata acctacaat 16320
agtttatgtta gtagagctgt cctggccaat taccgggccc tgcgactggtt cttaagcagt 16380
cactctctcc caagaacttt caaagttctc ttggttcttg aacactgaca 16440
tttctccgc aaagtttgaag cgttgcctct aagaaatttt agataacgttt ttctctcttg 16500
 tatattagtt aagatatttc cgaataacgc gcaattagcct ctagttttt gtagttttag 16560
ttaataaggg taatttgctag tgaagacactt aagtttgccc aagcttcaac ataactctaat 16620
tagatttgcag aagagagtatt gtcctgtgcac taaaaaattt ggaggaagcag aacacttctt 16680
caaccttacaa ggttttataag cagagacctc agctgtattg gttaactaat gttgagccag 16740
tagactctgaa caagttgctg cagtattttt ttttttattt gtaagtttctg 16800
agcatcgcaat gattttcata agatgttttctt ctagtttccgctaaaaag cgtggtatc 16860
tagttttact gcgtgagcttg gattgaactat attctagctt taaagtttata gagotggtata 16920
gtgtagcaag ctgtgcaagtt acaagcttgt tttaaatttg caaacaagag ttttagtggtg 16980
tccacccagc ttagagcagc acaactaagg cctttggctgc aacctataaa actaataagt 17040
aacttgctgc aacttttgcaaaa agtagagcgtg gttgcaaatg cacataataa catctatttt 17100
cttattgaaagt ttaaagaatt aggtttaaatg ttgaaacctg caaacaactg tttaaatac 17160
gtagccggct tacacccoa aaagagagtt ggtagggatt ttaggtgaa gaaacaagag 17220
ccttcgggact taaacttggt aatcagctgc tttctcaaggt aagttttctc aagttgctgac 17280
actttagtaat agcctctgat ggaacttgtag atacactcaat aggcctataa atttggactg 17340
tgatctcctaa acagacccgca gttgcaaat ttaacctcatt gagagctgta tccaagtaag 17400
tcaaatcttg gcaatcttgta aacgccaagga ttggcaaaat gtaagcagat aacactgtaa 17460
aagtctcagaa ttagttagtg ttagnotcag ggtgtgcatg cttgagcaota aacactcttc 17520
gctatttggtgt taaatactcgg aaggaccaag ttggtctcttg cagttctcaga gaaacaacct 17580
ctattcctacta taactcgaggt tttcgctttgt ggaagacattg ctggtcttttg gattttgttt 17640
ataacctc acttaatcttg gtaaactcagt ggggttaatttc ggtgactccta cacaatcaca 17700
atggtttgca tttgtaaktcg ctaggcaacag ctagtctcgg tttgccgatg ggttattgag 17760
cgcgttctcg tcgaattacta ttacactatctt ctggaagatg caactcgggt ttaacttacc 17820
ctcatataca aatagaggt gaaagcaatt catagctagt atattctaca cagctatac 17880
ttaaactcggtgt ttaaagcttaa aagtttgctta ttagatggcc aacccctaaatg 17940
gttataaatgc ttagaactgc gagaacctta aatttagatc ttagataag aatcaaatag 18000
taccccaagt caaagcagttt ggtgatcact ataacacgca aagagataag ttggtcatgtg 18060
gttctcttgat gttttctggt aatggtttggt attgatttc ccagcaactc ttagttgatga 18120
gtcacccac acgaataatttg agttggtttta acctaccggc ttgtaaggctg ttagcttggt 18180
atggttcaacat ctagcttctct cccacctcata aattctggtg ctgctactgtg 18240
aagctatgcc atcttttttc ctatcactcatt cgctctgcca gcacattttaa cggagacag 18300
tctgacccgta ccttgccatac ttagctagca aagattgtat ccaaaaagtgc aacatatggc 18360
gtgcgtttct taaataacgc gcaacactgt atccagattt ttagctctct ctataacgcct 18420
cctgtctctgc tggattcact tttttggtgtata ttaaaactaata cactccatat aattgtgga 18480
aaagttttttt aagcttctagc ttcagcgcaact atattgtgga taatatgtatg aagggcacatt 18540
atttttgctact ccgtagcca gaaatgccca atacttgcac tcggagataaa attttttgta 18600
tagctacgctag ccagttttttt tttaaccaactta aacctgtgcat aacacttgtaa 18660
cgtttgacgt ggagaaagca gcaactgcct gcacactgccc aacacaaccttg ctttggacaag 18720
ctttccggggtg agctgtctcg aatgcaattttc tttttggtgata ccaacccccc 18780
atatcgagaa atcgtctagc ttagctgcat atacagcact aagaccccaat ggccataata 18840
tgtgattgatc agtgatcact accttttttg aagctttctgc aaggttctgatg 18900
tagtttcgctag cagcagcttct aatgcttagttag gatcagcttagc aacctctgttg 18960
tccagacaagg ctatcctgctta aaagcttggag cgaacctgta ctgtttagta aagttgtaatg 19020
gtgctcttttgag tcaggtactt ccaacacttaga caacacgcggct ctcggctgatt gaaagttttt 19080
aacccctcttag cttgctttct cggacatgtc ttagaaaagt aaattttgta 19140
agtattgctga aagttgttagg ttcagcgctata ctagcttggt aagccctcaaat 19200
tatggggtttt acacactgttt ataggttatg gcagactttt aagctgccgaat aagtgttacag 19260
caagttctgt tactaatcct gatctctagt tcagtctaaa attatattgt taattttgta ttggcagaca 19320
atggtctca caagaacagt gtcacactgt gattttactt gttcagtatt tctttagaacc 19380
ttcgtagaa ccatacagaa gatgtttgct caataaagct ctaagtctga caagttcaca 19440
ttgatttctg tagaatctgtg gcagctcttt gtgatttctg gatttttctg 19500
atccacgct tcatacagcag tcggccagtt tctctctct tataaacact tataaagtc 19560
agaattggtg tatggactac atcggacact ctaaagtttt ttggtgtagtt 19620
ttggttgtt atgaaatcag gccagtttta cacacactg ccagcgacttc 19680
cagttcttgt ctcacagcaat tctctctctc gtttctta caacagctg 19740
tgctccaggg tagaatctgtg ccacatcagtt cgcatacact tctattct 19800
gctgtatttg aagatgtttg gctgcttttt ctcagctact tcaaatcag 19860
ataagacagag ccgccagattt gatctctatt tagatgtgtt gatttttctg 19920
dagcgagcactttg attcitagct ggctgtgtgtt tcattttctt tcttatttttt 19980
caagtttctt cggattctat attcgtgattt ggggttattt gatttctcatt 20040
cagttcgtca cagcaatctc cctttcttttt ttctttctt gcttttcttt 20100
gtcatcccagtt gcacactgtc cccatctttt ttctctctttt aagttttt 20160
daataatcg atttattttt ttgtggacttt cccatatttt tattaagtttt 20220
attgcgtttgt gctgtttctt tctttcttt gctttttttt tcttttttt 20280
cagttcagttgt ggttttgagc aatttttttt gttttttttt ttccttttta 20340
attgttttta atttttttttt aatggtttttt ctttctttttt aatggttttt 20400
tgctgttctt tgtgtgtttt aatatttttt tcttttttttt ttttttttttt 20460
tacacagtttc aatatttttt aatatttttt tcttttttttt ttttttttttt 20520
atttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 20580
atccagtttt tttttttttt tcttttttttt ttttttttttt ttttttttttt 20640
atcgtgggtg gtgtgtgttt tattttttttt tatttttttttt ttttttttttt 20700
attgttttttt tttttttttt ttttttttttt ttttttttttt ttttttttttt 20760
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 20820
atcctgtttttttttt ttttttttttt ttttttttttt ttttttttttt ttttttttttt 20880
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 20940
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21000
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21060
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21120
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21180
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21240
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21300
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21360
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21420
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21480
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21540
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21600
attttttttt aatatttttt aatatttttt tcttttttttt ttttttttttt 21660
acttgcgttg attataaatg atatggcaga actggccaaag gttttttatc taagttac 21720
gacccagctg ttagtgataa ttatctagca gacgccagtt tgtcctatltc agatacatct 21780
ggttcatag aagtccttttg tgtacaaggtt gaatagtttc ttaactatga taagttac 21840
cctttggaga agttcaacaa gcagtttggta gttttcctggg gtaattatgt aggtttcttt 21900
acttcatgta atggacggtt ttctcgagtt ctttgaacagc agttttacaat taataactct 21960
aataggcaac ctgtgctctag acgtttatat ctaggaatag tcggaaatgtt ccctctggt 22020
agttatatgta aatgtttgtat aaaaactcgag gtttcaatttg ctcacaatgtt aaccacaa 22080
ttggaacagt ttggtgcaac tttactttatgt gtagcgaatt actgtctactt aactaacag 22140
aatatatgtaa ctagtcataga tgaagctata ccaagggtga tgggtataagt ccaaatat 22200
tgggtgcaagt agtggcttgga caattctctg gattgtagaatt ggtgtttcaca acaataggg 22260
tgtttgttg gcacactatt gtctgtagta aataatagtg tgtcaaaaaga agatatggaa 22320
cattaataatatattttactataacctgcgt gctgttttta atacacccatt ttgaggtaa 22380
gttacgactcgt tgggagtttaa aatattttgc ctttcgatatgc cccgtcaggg 22440
cgttttatttatgaagctggtc ctcattttca acagtatgcgt atctggtgatt cccacgacgat 22500
gacgcacaca aaaaaacatag ctgggtttttc ttaggttttttc ttaaggaacot tgtcattgctg 22560
cgtgataata atggttgtgct tgttattggc cccattttatg aacgcgaat acaaatttgg 22620
taatctagtt ctcttttgct ctctttgctgt tttgtgttga taactgcagc tgggtgatata 22680
cottttgcaca caacacagcag ggtgtagaata atacactgaggt gttttacaca tgtcaactttg 22740
ttggaagactc aagaaaaatgt ctgctgttcct ttttattaga cctttaggtgc tattgcggaa 22800
gtttttagga gttacactctt acgttaacaa caaattcag aatggtttaaa taagcaagct 22860
getattttta ctgactaatg ctgctgaactt ataataataat tgggctgtat tttcttctat 22920
atccacgaca tttacacagcgt ctttgacgcg atacaacagca atgctctactt ggtatctttt 22980
ataactggtga gattgbagai ttttttttgc ttagatctcg taagcagcgg ggggcaattt 23040
agagtgcac aacagctggtg gttagctact ccaaaaaatta atagagttgtg taagtcacag 23100
ttatagggt actcctttttg ttgtaatagga gctagtcttga tcataaccent gaaattaaa 23160
cctattgtag aatgcctcttc ttataactcc gtagttttttgt caatgctcct 23220
goactgggg gttttttttgc aacgcgaagtgt aagtctctc aagtaacctg agtaccgctt 23280
aagggtagg gttttttttt ccaaaatgtt gtagttcctc acatcaacacg acagcaatag 23340
tatgacaaca gacgcatattg tgcagggagtt atgagaagcg ttaactttgtc tcaagccta 23400	taggaataag taaataagag cgtcaactct acatcgtgag acaatagatgt ttttcttttt 23460
aataaccgaa tgcacaatgg tgtggatgctg actaactaagat gctacaggaa cttttgcaca 23520
ftarccata cagtrcact tattcacagct gattgaaaattgacgccatc tttacgagt 23580
atcaggtgctc tttagatttac ttaaatagac ctttggaaaccc tttccactatt caaaacttat 23640
attaagggcct cttggtatgtg tctggttagcc atagttttcg cccattttatg ctttctattta 23700
atactacgtg gttttttttt cattgacgga tgtgtgtgtgt gtgtgttgtttc atggtgctgc 23760
attaagcctt caaaatacagcg tgggtttagg ccactttttc attacagacc tttggatatcc 23820
gattttgcat ctttccataac cagacccaaa aatgtttcatt aatgtttctta ctgtattcata 23880
cctttctaat agaattttttt tttttttttt gttacacttt gtaagtttaag tttttctgagtt 23940
tttattagct gttcacaaca ctaatacaag tttttcttttt cattataaat tgaacacatc 24000
agctagact gaccctttgt cacagcttag acctataagg cactatttga 24060
aacagttagg cagcgtattt aaataaatcg ttctaatatta cagcatattt caagtgtatt 24120
aacaacagaa gtaattggac cttgggtaga ttggtattcag agcagggta atttttggga 24180
aatagactca gctgaagatt ttcaggtgag aaggtaatttttttc aagtttaag 24240
aaatgaagat tttctctaca gctgttttata atttcttagg atttttacga ctttatttcttc 24300
taatgaagact aaccctggcca tttgtacccggt gctggtatgc tctctgtgta tttttgtata 24360
catgggtatg aatccoggga gctaagggta cagccttttgt atataaagtt taataagtta 24420
gaaactcaaa caatccggga ttagaagcgat ttatgtctaa cgaatttctt aagaactcgg 24480
ggataatita aaatccggga aatccgggag atgctcaacag agaacaatct tcctcttgac 24540
ttcgacaaagt cttttagtttttt ttaaatatat ttaaaccgtg inotgtttg 24600
cttttatcctaa taatactctca gtaatggtcttt tcaaaaggaagtaaatttttt attatacg 24660
aaatagatgt tggatattgtc cttttgccctttaacattctctgtagttttgcgaatctctctatttattgtcgg
atatacccaac caaacacaggg aaccttctggt gcggctatagc tcattcactgt gttggtgtgt 24700
cctctctcttggtagtattatgct catcagacat ttaaccctttaa ttaaccctttatgttcataggg
24740
ttgtcatttta aaacctcccaag atactgtggttta ggtcttttacct ttaaccttaa ttgcttcacac 24800
tgtaaattttctctttctggg aatggtatgtg ttgcacagttt taaatgcgatgtttagttgg 24860
ccttttttattctgttta ttttttttttctttaaaagttttttttaaagttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
ctgaaatgct gcaggagtgg gagataaca gcagotctcat cagcagcact tagtagagca 26460
cccacgctgg aagtttcgctc tgggcgcagg agtggttcttg agagttcttc tattgctgt 26520
gagcaaggg taatctgga ctcacgtaaga aaggttctcgc gactacaaaa ggcataagct 26580
gatggaatgg ccacgcgcgtc gtattgcagc ggaactattc aacactaatatt taaggtgtag 26640
caacagttgtc gtccgctagc taagagtaag gcagggaaatt tggaggtagta caagagat 26700
gaggaaggtg ttaaggtagtg gcgccttaca gcattgcata accagtctcc tagcagcct 26760
gttctcttt tcggaaggtg agtgcagccac agacctcaacc cagatgggct gcacttggaa 26820
tttgaatttc taactgttggt ccacgctgtg gatcgcagcttg tagataatta tgaataaat 26880
tggtgctagct gtggtgtagct tgtgaagaca gctaacaaagattgattgacc agaacaaag 26940
tacgcctcaca gttgcacacc tgcaacaaaga ggaattctcgc gacgcgcacag cagacgcacg 27000
cctaaaggg aagaaagccc aagaaagccg gatggaatgag tggataacagc accctca 27060
gatggaaggac gaaacatcgac acgcttggaa ttggtggtgtg aacccaaaggt aattaactg 27120
ggggatcctcg cccttgggaga gatggaaatt tgaag ataataattc aatatatttacgt 27180
agataggtcat gtagctgtgt tacaactacattctgtggcca gggaatgtgtaaattgg 27240
acacttagcct cgggaagacg acggtagaccc cttggtatatt aatctagtttc aatcttttaatg 27300
ttagtttaag taaggtgatag aatgcagcag ggcgggacgc cgccagtttg 27360
gaccggaggt acacagactag gcgcctcattag gcgggaagacg ctaaatattttgatgatta 27420
agtttaagct gtagttgatggtgtagata ataggtcagtt atagagtttagaagcgaaaaa 27480
aAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27500

<210> SEQ ID NO 2
<211> LENGTH: 435
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus
<400> SEQUENCE: 2

totaagtcgc atagagacgaa ggaagtggat gcagctggca ttctctcact ttgctttcttt 60
goagtacgtc tgtggctaca atatgtgtaa tattgccag cagtaatca acctttaggt 120
aacgtagataa aatgcagcag aacactaaat ggtagttggt ttcgtctgac atacaagc 180
agtttcacagc acctctggcgc gcagggaaat ttagttgagc gcagggc 240
catatacgc acctctggcgc gcagggaaat ttagttgagc gcagggc 300
ttttgccaaa taacctacagc gcagggaaat ttagttgagc gcagggc 360
tgcactgtgt ttgctcggttg gatgttggat gcagctgtgct gcagctaacct tgaacaacct 420
aaacctttcca ttccag 435

<210> SEQ ID NO 3
<211> LENGTH: 1563
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus
<400> SEQUENCE: 3

ggtaagcagct tgtgtaaaatt tggcaaaaaag gaggtaggtg gtggtcaccc agcttaagct 60
gtgaacacta aaggtctttgc tgcacacttat aaagtttaatg atgaacttttc ggcaactgttt 120
aacggtggagc tgtgctccaga aataacatat aaacatatta tttctttggtt aggcttttaag 180
atgaaggtta atgtgagaaa ttgcagcctc atgtttatatc ccaaaactgtaa gggcctccccg 240
<table>
<thead>
<tr>
<th>seq</th>
<th>sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>300</td>
<td>aacgtaagag gttggttagg ttggtgtga taagcacaac atgcttggag tactaactat</td>
</tr>
<tr>
<td>360</td>
<td>ggtactaacc tgtgctttaac aagtggcttt tcaccttggtg cagacttggct agtacgctt</td>
</tr>
<tr>
<td>420</td>
<td>gaggcactgg tagaatctcco aatagccaat aatatttgagc cttgtaatct taacagcactt</td>
</tr>
<tr>
<td>480</td>
<td>coagcagac aatatttacc aagcggttagg ttgctaaac aatgcttggg tactaactat</td>
</tr>
<tr>
<td>540</td>
<td>gtaagcccaaa gatagtggtcg caaattgtagg gataacacgtg gcacagtcttc atgacgtgta</td>
</tr>
<tr>
<td>600</td>
<td>gttgtgcgta cggactcggc tcggctcaggcg tctacaactt taagcgttcgatt gctttatata</td>
</tr>
<tr>
<td>660</td>
<td>ggcagggcg aagttggttc ttgctggtctt agagcacaac cttaataactt taatctcctg</td>
</tr>
<tr>
<td>720</td>
<td>gctttatctgt gttggaagatg cttgttggtt gttgatcggg ttggactacgcc tttgatattc</td>
</tr>
<tr>
<td>780</td>
<td>gatatacgttg aagttggttt tcctgtttaa ctcaaaattta accatgatct gcacgttaat</td>
</tr>
<tr>
<td>840</td>
<td>gtcagatggca gacgcatgtg aggttcttct ggtcataatta tggctgctt cttgcaactt</td>
</tr>
<tr>
<td>900</td>
<td>aataatgtact ttgtgctaaag tctagactgg gatgtcatactt accctcatac agcaccagct</td>
</tr>
<tr>
<td>960</td>
<td>gatagcactg acatatcctt acatctgattg cagcaaatc ttaaatattg acctcacttg</td>
</tr>
<tr>
<td>1020</td>
<td>gttcttaaag acatgggttt ctctatgata ggtgccagaat aaggtaattag atgtgtgtag</td>
</tr>
<tr>
<td>1080</td>
<td>cgttgagacct taatattgctg atctttatgat cgtattgctg gagaattgta cacgcaaaatc</td>
</tr>
<tr>
<td>1140</td>
<td>tttgagatag actataataa ctaaaccaca aagttgtggt atgcttttct tttggtttggg</td>
</tr>
<tr>
<td>1200</td>
<td>aatgtttgtg tttgatgtagc tccggagaatt tccgtgcttc tctatctgctg ttgatgctgaa</td>
</tr>
<tr>
<td>1260</td>
<td>ttgatgctgt ttaacccctc tcggctgata ggtctgtagt tgattgctt ccaacagcactt</td>
</tr>
<tr>
<td>1320</td>
<td>ttcacncac ctaatattga ttcgctcattg tctctatttt tctgaagctg gctcatttttt</td>
</tr>
<tr>
<td>1380</td>
<td>ttctatgact cctccttggtg cagacaccag ctaatgtggt ttggcttctt ctaaatattat</td>
</tr>
<tr>
<td>1440</td>
<td>toattattca gcaaccatag ttcataacaa atacagatag gactctggctt tttgctaacaa</td>
</tr>
<tr>
<td>1500</td>
<td>cacgcaaaac tgcagcactgg tttggtgctg ttttataagt cgacgttacgc ttgctgtgttt</td>
</tr>
<tr>
<td>1560</td>
<td>aatcctcttttt tttatataa ctaaaccaca aagttgtgtg atgcttttct tttggtttggg</td>
</tr>
<tr>
<td>1563</td>
<td>cag</td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 4
<211> LENGTH: 1014
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus
<400> SEQUENCE: string
gattctgatg tcaatgcaaaa ttatattgta ttggcagaca atgtcttcca caagcagtg 840
tgatctggtg ttgatgctg gcttgatgat ttctttgaac ttcttagaaa catactgaaa 900
gagtagta gtaataagtc taaagtgtgta acaagtgtca taagattaca tagcataaat 960
ttttatgatt ggcttgaaga tggcattatt aaaaacagtt atccacagct tcarr 1014

<210> SEQ ID NO 5
<211> LENGTH: 909
<212> TYPE: DNA
<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 5

tcaaatgagaa cgtctgggta taattacgct gccacattata aagttccagaa tttgtttagt 60
gaacctgcac acacctctaa tttggtgtgtg gaaatagctg tgcagaaagc ttatattgag 120
aatgtgcagaa aagttccagaa acctctctcag ccctccagtaa acacccgtaa craracrccac 180
cataatagc gagatagctg tttggtagt ggaattgaca aaggagtt ggctttacagt 240
aatgtcttta aacaatgctg cccagaaggg acctctcctgctgataattgta atttgatgcc 300
taatgttgctg attcacagtt ttctttggag ttagttcagt caaataatata aacgagacac 360
aatgtgatgtc aataatcctt gctttcagt gtagtttctgctgatgaatgta cacagacacgagttgcaagaa 420
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 480
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 540
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 600
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 660
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 720
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 780
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 840
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 900
aatgatgtgaag ccaaaacctg gcaaatagct gcaaatagctg cacagacagtt tttggtcagaa 960

<210> SEQ ID NO 6
<211> LENGTH: 145
<212> TYPE: PRT
<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 6

Ser Lys Gly His Glu Thr Glu Glu Val Asp Ala Val Gly Ile Leu Ser 1 5 10 15
Leu Cys Ser Phe Ala Val Asp Pro Ala Asp Thr Tyr Cys Lys Tyr Val 20 25 30
Ala Ala Gly Asn Gln Pro Leu Gly Asn Cys Val Lys Met Leu Thr Val 35 40 45
His Asn Gly Ser Gly Phe Ala Ile Thr Ser Lys Pro Ser Pro Thr Pro 50 55 60
Asp Gln Asp Ser Tyr Gly Gly Ala Ser Val Cys Leu Tyr Cys Arg Ala 65 70 75 80
His Ile Ala His Pro Gly Gly Ala Gly Asn Leu Asp Gly Arg Cys Gln 85 90 95
Phe Lys Gly Ser Phe Val Gln Ile Pro Thr Thr Glu Lys Asp Pro Val 100 105 110
Gly Phe Cys Leu Arg Asn Lys Val Cys Thr Val Cys Gln Cys Thr Ile
Gly Tyr Gly Cys Gln Cys Asp Ser Leu Arg Gln Pro Lys Pro Ser Val
130 135 140

Gly
145

<210> SEQ ID NO 7
<211> LENGTH: 521
<212> TYPE: PRT
<213> ORGANISM: Infectious bronchitis virus
<400> SEQUENCE: 7

Gly Thr Gly Leu Phe Lys Ile Cys Asn Lys Glu Phe Ser Gly Val His
1 5 10 15

Pro Ala Tyr Ala Val Thr Thr Lys Ala Leu Ala Ala Thr Tyr Lys Val
20 25 30

Asn Asp Glu Leu Ala Ala Val Asn Val Glu Ala Gly Ser Glu Ile
35 40 45

Thr Tyr Lys His Leu Ile Ser Leu Leu Gly Phe Lys Met Ser Val Asn
50 55 60

Val Glu Gly Cys His Asn Met Phe Ile Thr Arg Asp Glu Ala Ile Arg
65 70 75 80

Asn Val Arg Gly Trp Val Gly Phe Asp Val Glu Ala Thr His Ala Cys
85 90 95

Gly Thr Asn Ile Gly Thr Asn Leu Pro Phe Glu Val Gly Phe Ser Thr
100 105 110

Gly Ala Asp Phe Val Thr Asp Val Gly Leu Val Asp Thr Ser Ile
115 120 125

Gly Asn Asn Phe Glu Pro Val Asn Ser Lys Ala Asp Pro Gly Glu Gln
130 135 140

Phe Asn His Leu Arg Ala Leu Phe Lys Ser Ala Lys Pro Trp His Val
145 150 155 160

Val Arg Pro Arg Ile Val Gln Met Leu Ala Asp Asn Leu Cys Asn Val
165 170 175

Ser Asp Cys Val Val Phe Val Thr Trp Cys His Gly Leu Glu Leu Thr
180 185 190

Thr Leu Arg Tyr Phe Val Lys Ile Gly Lys Asp Gln Val Cys Ser Cys
195 200 205

Gly Ser Arg Ala Thr Thr Asn Ser His Thr Glu Ala Tyr Ala Cys
210 215 220

Trp Lys His Cys Leu Gly Phe Asp Phe Val Tyr Asn Pro Leu Leu Val
225 230 235 240

Asp Ile Gln Glu Trp Gly Tyr Ser Gly Asn Leu Glu Phe Asn His Asp
245 250 255

Leu His Cys Asn Val His Gly His Ala His Val Ala Ser Ala Asp Ala
260 265 270

Ile Met Thr Arg Cys Leu Ala Ile Asn Ala Phe Cys Gln Asp Val
275 280 285

Asn Trp Asp Leu Thr Tyr Pro His Ile Ala Asn Glu Asp Glu Val Asn
290 295 300

Ser Ser Cys Arg Tyr Leu Gln Arg Met Tyr Leu Asn Ala Cys Val Asp
305 310 315 320

Ala Leu Lys Val Asn Val Val Tyr Asp Ile Gly Asn Pro Lys Gly Ile
325 330 335
Lys Cys Val Arg Arg Gly Asp Leu Asn Phe Arg Phe Tyr Asp Lys Asn 340 345 350
Pro Ile Val Pro Asn Val Lys Gln Phe Glu Tyr Asp Tyr Asn Gln His 355 360 365
Lys Asp Lys Phe Ala Asp Gly Leu Asn Met Phe Trp Asn Cys Asn Val 370 375 380
Asp Cys Tyr Pro Asp Asn Ser Leu Val Cys Tyr Arg Tyr Asp Thr Arg Asn 385 390 395 400
Leu Ser Val Phe Asn Leu Pro Gly Cys Asn Gly Gly Ser Leu Tyr Val 405 410 415
Asn Lys His Ala Phe His Thr Pro Lys Phe Asp Arg Thr Ser Phe Arg 420 425 430
Asn Leu Lys Ala Met Pro Phe Phe Tyr Asp Ser Ser Pro Cys Glu 435 440 445 450
Thr Ile Gln Leu Asp Gly Val Ala Gln Asp Leu Val Ser Leu Ala Thr 455 460
Lys Asp Cys Ile Thr Lys Cys Asn Ile Gly Gly Ala Val Cys Lys 465 470 475 480
His Ala Gln Met Tyr Ala Asp Phe Val Thr Ser Tyr Asn Ala Val 485 490 495
Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn 500 505 510
Leu Trp Lys Ser Phe Ser Ala Leu Gln 515 520

<210> SEQ ID NO 8
<211> LENGTH: 338
<212> TYPE: PRT
<213> ORGANISM: Infectious bronchitis virus

<400> SEQUENCE: 8
Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp 1 5 10 15
Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe 20 25 30
Val Ile Asp Glu Gly Val Glu Lys Ala Val Phe Asn Gln Thr Ile 35 40 45
Leu Pro Thr Ser Val Ala Phe Glu Tyr Ala Asn Arg Asn Ile Arg 50 55 60
Thr Leu Pro Asn Asn Arg Ile Leu Lys Leu Gly Leu Gly Val Asp Val Thr 65 70 75 80
Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg 85 90 95
Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu 100 105 110
Ile Val Leu Tyr Asp Arg Asp Tyr Gly Asp Tyr Gln Ser Phe Leu Ala 115 120 125
Ala Asp Asn Ala Val Leu Val Ser Thr Gln Cys Tyr Asp Tyr Ser 130 135 140
Tyr Val Glu Ile Pro Ser Asn Leu Leu Val Gln Asn Gly Ile Pro Leu 145 150 155 160
Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe 165 170 175
Val Thr Leu Pro Asn Thr Leu Asn Thr Gln Gly Arg Ser Tyr Glu Thr 180 185 190
<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phe Glu Pro Arg Ser Asp Val Glu Arg Asp Phe Leu Asp Met Ser Glu</td>
<td>195 - 205</td>
</tr>
<tr>
<td>Glu Ser Phe Val Glu Lys Tyr Gly Lys Glu Leu Gly Leu Glu His Ile</td>
<td>210 - 220</td>
</tr>
<tr>
<td>Leu Tyr Gly Glu Val Asp Lys Pro Gln Leu Gly Gly Leu His Thr Val</td>
<td>225 - 240</td>
</tr>
<tr>
<td>Ile Gly Met Cys Arg Leu Leu Arg Ala Asn Lys Leu Asn Ala Lys Ser</td>
<td>245 - 255</td>
</tr>
<tr>
<td>Val Thr Asn Ser Asp Ser Asp Val Met Gln Asn Tyr Phe Val Leu Ala</td>
<td>260 - 270</td>
</tr>
<tr>
<td>Asp Asn Gly Ser Tyr Lys Gln Val Cys Thr Val Val Asp Leu Leu</td>
<td>275 - 285</td>
</tr>
<tr>
<td>Asp Asp Phe Leu Glu Leu Arg Asn Ile Leu Lys Gly Thr Gly Thr</td>
<td>290 - 300</td>
</tr>
<tr>
<td>Asn Lys Ser Lys Val Thr Val Thr Ser Ile Asn Tyr His Ser Ile Asn</td>
<td>310 - 320</td>
</tr>
<tr>
<td>Phe Met Thr Trp Phe Glu Asp Gly Ile Ile Lys Thr Cys Tyr Pro Gln</td>
<td>325 - 335</td>
</tr>
<tr>
<td>Leu Gln</td>
<td>340</td>
</tr>
</tbody>
</table>

SEQ ID NO 9
LENGTH: 302
TYPE: PRT
ORGANISM: Infectious bronchitis virus

SEQUENCE: 9

<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Ala Trp Thr Cys Gly Tyr Asn Met Pro Glu Leu Tyr Lys Val Gln</td>
<td>1 - 15</td>
</tr>
<tr>
<td>Asn Cys Val Met Glu Pro Cys Asn Ile Pro Asn Tyr Gly Val Gly Ile</td>
<td>20 - 30</td>
</tr>
<tr>
<td>Ala Leu Pro Ser Gly Ile Met Asn Val Ala Lys Tyr Thr Gln Leu</td>
<td>35 - 45</td>
</tr>
<tr>
<td>Cys Gln Tyr Leu Ser Lys Thr Thr Met Cys Val Pro His Asn Met Arg</td>
<td>50 - 60</td>
</tr>
<tr>
<td>Val Met His Phe Gly Ala Gly Ser Asp Lys Gly Val Ala Pro Gly Ser</td>
<td>65 - 80</td>
</tr>
<tr>
<td>Thr Val Leu Lys Gln Trp Leu Pro Glu Gly Thr Leu Val Asp Asn</td>
<td>85 - 95</td>
</tr>
<tr>
<td>Asp Ile Val Asp Tyr Val Ser Asp Ala His Val Ser Val Leu Ser Asp</td>
<td>100 - 110</td>
</tr>
<tr>
<td>Cys Asn Lys Tyr Lys Thr Glu His Lys Phe Asp Leu Val Ile Ser Asp</td>
<td>115 - 125</td>
</tr>
<tr>
<td>Met Tyr Thr Asp Asn Ser Lys Arg Lys His Gln Gly Val Ile Ala</td>
<td>130 - 140</td>
</tr>
<tr>
<td>Asn Asn Gly Asn Asp Val Phe Ile Tyr Leu Ser Ser Phe Leu Arg</td>
<td>145 - 155</td>
</tr>
<tr>
<td>Asn Asn Leu Ala Leu Gly Ser Phe Ala Val Lys Val Thr Glu Thr</td>
<td>160 - 170</td>
</tr>
<tr>
<td>Ser Trp His Gln Val Leu Tyr Asp Ile Ala Gln Asp Cys Ala Trp Trp</td>
<td>175 - 190</td>
</tr>
<tr>
<td>Thr Met Phe Cys Thr Ala Val Asn Ala Ser Ser Ser Gly Ala Phe Leu</td>
<td>195 - 205</td>
</tr>
<tr>
<td>Val Gly Val Asn Tyr Leu Gly Ala Ser Glu Lys Val Lys Val Ser Gly</td>
<td>210 - 220</td>
</tr>
</tbody>
</table>
Lys Thr Leu His Ala Asn Tyr Ile Phe Trp Arg Asn Cys Asn Tyr Leu
225 230 235 240
Gln Thr Ser Ala Tyr Ser Ile Phe Asp Val Ala Lys Phe Asp Leu Arg
245 250 255
Leu Lys Ala Thr Pro Val Val Asn Leu Lys Thr Glu Gln Lys Thr Asp
260 265 270
Leu Val Phe Asn Leu Ile Lys Cys Gly Lys Leu Val Arg Asp Val
275 280 285
Gly Asn Thr Ser Phe Thr Ser Asp Ser Phe Val Cys Thr Met
290 295 300

<210> SEQ ID NO 1
<211> LENGTH: 145
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Mutated Nsp10 sequence

<400> SEQUENCE: 10
Ser Lys Gly His Glu Thr Glu Glu Val Asp Ala Val Gly Ile Leu Ser
1 5 10 15
Leu Cys Ser Phe Ala Val Asp Pro Ala Asp Thr Tyr Cys Lys Tyr Val
20 25 30
Ala Ala Gly Asn Gln Pro Leu Gly Asn Cys Val Leu Met Leu Thr Val
35 40 45
His Asn Gly Ser Gly Phe Ala Ile Thr Ser Lys Pro Ser Pro Thr Pro
50 55 60
Asp Glu Asp Ser Tyr Gly Gly Ala Ser Val Cys Leu Tyr Cys Arg Ala
65 70 75 80
His Ile Ala His Leu Gly Gly Ala Gly Asn Leu Asp Gly Arg Cys Gln
85 90 95
Phe Lys Gly Ser Phe Val Gln Ile Pro Thr Thr Glu Lys Asp Pro Val
100 105 110
Gly Phe Cys Leu Arg Asn Lys Val Cys Thr Val Cys Gln Cys Trp Ile
115 120 125
Gly Tyr Gly Cys Gln Cys Asp Ser Leu Arg Gln Pro Lys Pro Ser Val
130 135 140
Gln 145

<210> SEQ ID NO 11
<211> LENGTH: 521
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Mutated Nsp14 sequence

<400> SEQUENCE: 11
Gly Thr Gly Leu Phe Lys Ile Cys Asn Lys Glu Phe Ser Gly Val His
1 5 10 15
Pro Ala Tyr Ala Val Thr Thr Lys Ala Leu Ala Ala Thr Tyr Lys Val
20 25 30
Asn Asp Glu Leu Ala Ala Val Asn Val Glu Ala Gly Ser Glu Ile
35 40 45
Thr Tyr Lys His Leu Ile Ser Leu Leu Gly Phe Lys Met Ser Val Asn
50 55 60
Val Glu Gly Cys His Asn Met Phe Ile Thr Arg Asp Glu Ala Ile Arg
Thr Ala Gly Phe Thr Phe Trp Val Thr Asn Asn Phe Asn Pro Tyr Asn
 500 505 510
Leu Trp Lys Ser Phe Ser Ala Leu Gln
 515 520

<210> SEQ ID NO 12
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Mutated Nmp15 sequence

<400> SEQUENCE: 12
Ser Ile Asp Asn Ile Ala Tyr Asn Met Tyr Lys Gly Gly His Tyr Asp
 1  5 10 15
Ala Ile Ala Gly Glu Met Pro Thr Ile Val Thr Gly Asp Lys Val Phe
 20  25  30
Val Ile Asp Gln Gly Val Glu Lys Ala Val Phe Phe Asn Gln Thr Ile
 35  40  45
Leu Pro Thr Ser Val Ala Phe Glu Leu Tyr Ala Lys Arg Asn Ile Arg
 50  55  60
Thr Leu Pro Asn Arg Ile Leu Lys Gly Leu Gly Val Asp Val Thr
 65  70  75  80
Asn Gly Phe Val Ile Trp Asp Tyr Thr Asn Gln Thr Pro Leu Tyr Arg
 85  90  95
Asn Thr Val Lys Val Cys Ala Tyr Thr Asp Ile Glu Pro Asn Gly Leu
100 105 110
Ile Val Leu Tyr Asp Asp Arg Gly Asp Tyr Gln Ser Phe Leu Ala
115 120 125
Ala Asp Asn Ala Val Leu Val Ser Thr Gin Cys Tyr Lys Arg Tyr Ser
130 135 140
Tyr Val Glu Ile Pro Ser Asn Leu Val Gin Asn Gly Ile Pro Leu
145 150 155 160
Lys Asp Gly Ala Asn Leu Tyr Val Tyr Lys Arg Val Asn Gly Ala Phe
165 170 175
Val Thr Leu Pro Asn Thr Ile Asn Thr Gin Gly Arg Ser Tyr Glu Thr
180 185 190
Phe Glu Pro Arg Ser Asp Val Glu Arg Asp Phe Leu Asp Met Ser Glu
195 200 205
Glu Ser Phe Val Glu Lys Tyr Gly Lys Glu Leu Gln His Ile
210 215 220
Leu Tyr Gly Glu Val Asp Lys Pro Gin Leu Gly Lys His Thr Val
225 230 235 240
Ile Gly Met Cys Arg Leu Leu Arg Ala Asn Lys Leu Asn Ala Lys Ser
245 250 255
Val Thr Asn Ser Asp Ser Asp Val Met Gin Asn Tyr Phe Val Leu Ala
260 265 270
Asp Asn Gly Ser Tyr Lys Gin Val Cys Thr Val Val Asp Leu Leu Leu
275 280 285
Asp Asp Phe Leu Glu Leu Leu Arg Asn Ile Leu Lys Gly Tyr Gly Thr
290 295 300
Asn Lys Ser Lys Val Thr Val Ser Ile Asp Tyr His Ser Ile Asn
305 310 315 320
Phe Met Thr Trp Phe Glu Asp Gly Ile Ile Lys Thr Cys Tyr Pro Gin
325 330 335
The invention claimed is:

1. A live, attenuated coronavirus comprising a variant replicase gene encoding polypeptides comprising a mutation in one or both of non-structural protein(s) nsp-10 and nsp-14, wherein the variant replicase gene encodes a protein comprising an amino acid mutation of Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7.

2. The coronavirus according to claim 1 wherein the variant replicase gene encodes a protein comprising one or more amino acid mutations selected from:

   a. an amino acid mutation of Leu to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and
an amino acid mutation of Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

3. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Len to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

4. The coronavirus according to claim 1 wherein the replicase gene encodes a protein comprising the amino acid mutations Pro to Leu at the position corresponding to position 85 of SEQ ID NO: 6; Val to Leu at the position corresponding to position 393 of SEQ ID NO: 7; Len to Ile at the position corresponding to position 183 of SEQ ID NO: 8; and Val to Ile at the position corresponding to position 209 of SEQ ID NO: 9.

5. The coronavirus according to claim 1 wherein the replicase gene comprises at least one nucleotide substitutions selected from:

   - C to T at nucleotide position 12137; and
   - G to C at nucleotide position 18114;

   compared to the sequence shown as SEQ ID NO: 1;

   and optionally, comprises one or more nucleotide substitutions selected from T to A at nucleotide position 19047; and

   - G to A at nucleotide position 20139;

   compared to the sequence shown as SEQ ID NO: 1.

6. The coronavirus according to claim 1 which is an infectious bronchitis virus (IBV).

7. The coronavirus according to claim 1 which is IBV M41.

8. The coronavirus according to claim 7, which comprises an S protein at least, part of which is from an IBV serotype other than M41.

9. The coronavirus according to claim 8, wherein the S1 subunit is from an IBV serotype other than M41.

10. The coronavirus according to claim 8, wherein the S protein is from an IBV serotype other than M41.

11. The coronavirus according to claim 1 which has reduced pathogenicity compared to a coronavirus expressing a corresponding wild-type replicase, wherein the virus is capable of replicating without being pathogenic to the embryo when administered to an embryonated egg.

12. A variant replicase gene as defined in claim 1.

13. A protein encoded by a variant coronavirus replicase gene according to claim 12.

14. A plasmid comprising a replicase gene according to claim 12.

15. A method for making the coronavirus according to claim 1 which comprises the following steps:

   (i) transfecting a plasmid according to claim 14 into a host cell;

   (ii) infecting the host cell with a recombinant virus comprising the genome of a coronavirus strain with a replicase gene;

   (iii) allowing homologous recombination to occur between the replicase gene sequences in the plasmid and the corresponding sequences in the recombinating virus genome to produce a modified replicase gene; and

   (iv) selecting for recombinant viruses comprising the modified replicase gene.

16. The method according to claim 15, wherein the recombinating virus is a vaccinia virus.

17. The method according to claim 15 which also includes the step:

   (v) recovering recombinant coronavirus comprising the modified replicase gene from the DNA from the recombinating virus from step (iv).

18. A cell capable of producing a coronavirus according to claim 1.

19. A vaccine comprising a coronavirus according to claim 1 and a pharmaceutically acceptable carrier.

20. A method for treating and/or preventing a disease in a subject which comprises the step of administering a vaccine according to claim 19 to the subject.

21. The method of claim 20, wherein the disease is infectious bronchitis (IB).

22. The method according to claim 20 wherein the method of administration is selected from the group consisting of: eye drop administration, intranasal administration, drinking water administration, post-hatch injection and in ovo injection.

23. The method according to claim 21 wherein the administration is in ovo vaccination.

24. A method for producing a vaccine according to claim 19 which comprises the step of infecting a cell according to claim 18 with a coronavirus according to claim 1.

25. The coronavirus according to claim 1, further comprising a mutation in one or both of nsp-15 and nsp-16.

* * * * *